US10709718B2 - Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof - Google Patents
Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof Download PDFInfo
- Publication number
- US10709718B2 US10709718B2 US16/025,199 US201816025199A US10709718B2 US 10709718 B2 US10709718 B2 US 10709718B2 US 201816025199 A US201816025199 A US 201816025199A US 10709718 B2 US10709718 B2 US 10709718B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- aryl
- pharmaceutically acceptable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 title abstract description 36
- 102000015868 Diacylglycerol O-acyltransferase 1 Human genes 0.000 title abstract description 36
- 239000003112 inhibitor Substances 0.000 title abstract description 13
- -1 thiohydroxy pyridines Chemical class 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 14
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 14
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims abstract description 7
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 6
- 230000000291 postprandial effect Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 120
- 125000003118 aryl group Chemical group 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000002947 alkylene group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 208000008589 Obesity Diseases 0.000 claims description 27
- 235000020824 obesity Nutrition 0.000 claims description 27
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 14
- 239000003981 vehicle Substances 0.000 claims description 13
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 10
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 229910003813 NRa Inorganic materials 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 7
- 229940125708 antidiabetic agent Drugs 0.000 claims description 7
- 239000003472 antidiabetic agent Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000883 anti-obesity agent Substances 0.000 claims description 6
- 229940125710 antiobesity agent Drugs 0.000 claims description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052705 radium Inorganic materials 0.000 claims description 6
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 235000012631 food intake Nutrition 0.000 claims description 5
- 230000037406 food intake Effects 0.000 claims description 5
- 150000002367 halogens Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052701 rubidium Inorganic materials 0.000 claims description 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims 2
- QVFWZNCVPCJQOP-UHFFFAOYSA-N chloralodol Chemical compound CC(O)(C)CC(C)OC(O)C(Cl)(Cl)Cl QVFWZNCVPCJQOP-UHFFFAOYSA-N 0.000 claims 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 10
- 235000005911 diet Nutrition 0.000 abstract description 8
- 206010033307 Overweight Diseases 0.000 abstract description 7
- 230000037213 diet Effects 0.000 abstract description 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 6
- 206010036049 Polycystic ovaries Diseases 0.000 abstract description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract description 4
- 208000018914 glucose metabolism disease Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 230000001668 ameliorated effect Effects 0.000 abstract description 2
- 150000003230 pyrimidines Chemical class 0.000 abstract description 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 229910001868 water Inorganic materials 0.000 description 36
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 19
- 125000003710 aryl alkyl group Chemical group 0.000 description 18
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 16
- 125000004122 cyclic group Chemical group 0.000 description 15
- 229940127193 DGAT1 inhibitor Drugs 0.000 description 14
- 0 [1*]C1=CC(C)=C2N=C(C(C)(C)C)C([2*])([3*])CC2=N1 Chemical compound [1*]C1=CC(C)=C2N=C(C(C)(C)C)C([2*])([3*])CC2=N1 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 210000001842 enterocyte Anatomy 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000009885 systemic effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 229910003827 NRaRb Inorganic materials 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 150000001982 diacylglycerols Chemical class 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- SLZVXWBIEALGIW-WGSAOQKQSA-N CC(C)OP(=O)(C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4Cl)C=C2)CC1)OC(C)C Chemical compound CC(C)OP(=O)(C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4Cl)C=C2)CC1)OC(C)C SLZVXWBIEALGIW-WGSAOQKQSA-N 0.000 description 4
- ZUTYKXCSUCFVKJ-UHFFFAOYSA-N ClC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(Cl)=N1 Chemical compound ClC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(Cl)=N1 ZUTYKXCSUCFVKJ-UHFFFAOYSA-N 0.000 description 4
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 description 4
- 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000003629 gastrointestinal hormone Substances 0.000 description 4
- 238000005462 in vivo assay Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000013222 sprague-dawley male rat Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000009482 thermal adhesion granulation Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DAOUTAVCZZVELX-UHFFFAOYSA-N CCOC1=NC=NC2=C1N=CN2C1=CC=C(C2CCC(CP(=O)(O)O)CC2)C=C1 Chemical compound CCOC1=NC=NC2=C1N=CN2C1=CC=C(C2CCC(CP(=O)(O)O)CC2)C=C1 DAOUTAVCZZVELX-UHFFFAOYSA-N 0.000 description 3
- BKCKBKYXRZHQOS-UHFFFAOYSA-N CCP(=O)(O)CC(C)(C)C Chemical compound CCP(=O)(O)CC(C)(C)C BKCKBKYXRZHQOS-UHFFFAOYSA-N 0.000 description 3
- VPUCXNBWZTYDPE-SHTZXODSSA-N CN(C)C1=NC=NC2=C1N=CN2C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1.O=C(O)C(F)(F)F Chemical compound CN(C)C1=NC=NC2=C1N=CN2C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1.O=C(O)C(F)(F)F VPUCXNBWZTYDPE-SHTZXODSSA-N 0.000 description 3
- XJPHBZXZHVQBML-UHFFFAOYSA-N ClC1=NC=NC2=C1N=CN2C1=CC=C(C2CCCCC2)C=C1 Chemical compound ClC1=NC=NC2=C1N=CN2C1=CC=C(C2CCCCC2)C=C1 XJPHBZXZHVQBML-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- LTVWWJIPTUWCOT-UHFFFAOYSA-N NC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(Cl)=N1 Chemical compound NC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(Cl)=N1 LTVWWJIPTUWCOT-UHFFFAOYSA-N 0.000 description 3
- VWCWYSJFDNRDRP-UHFFFAOYSA-N NC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(N)=N1 Chemical compound NC1=NC2=C(N=CN2C2=CC=C(C3CCCCC3)C=C2)C(N)=N1 VWCWYSJFDNRDRP-UHFFFAOYSA-N 0.000 description 3
- WKNQBJLTZFQCEZ-UHFFFAOYSA-N NC1=NC=NC2=C1N=CN2C1=CC=C(C2CCCCC2)C=C1 Chemical compound NC1=NC=NC2=C1N=CN2C1=CC=C(C2CCCCC2)C=C1 WKNQBJLTZFQCEZ-UHFFFAOYSA-N 0.000 description 3
- MESZIVFCZMARLW-JOCQHMNTSA-N NC1=NC=NC2=C1N=CN2C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1 Chemical compound NC1=NC=NC2=C1N=CN2C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1 MESZIVFCZMARLW-JOCQHMNTSA-N 0.000 description 3
- FGANPPFNHPRTMU-QAQDUYKDSA-N O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(NC4=CC=CC=C4)=NC4=C3N=CN=C4Cl)C=C2)CC1 Chemical compound O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(NC4=CC=CC=C4)=NC4=C3N=CN=C4Cl)C=C2)CC1 FGANPPFNHPRTMU-QAQDUYKDSA-N 0.000 description 3
- NFHIAMAUWZLEBA-IYARVYRRSA-N O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4NC3=CC=CC=C3)C=C2)CC1 Chemical compound O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4NC3=CC=CC=C3)C=C2)CC1 NFHIAMAUWZLEBA-IYARVYRRSA-N 0.000 description 3
- SRNFXRGJOOWGHH-MXVIHJGJSA-N O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4NCC3=CC=CC=C3)C=C2)CC1 Chemical compound O=C(O)C(F)(F)F.O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4NCC3=CC=CC=C3)C=C2)CC1 SRNFXRGJOOWGHH-MXVIHJGJSA-N 0.000 description 3
- FBASOTSZQWXLEH-HAQNSBGRSA-N O=C1NC2=C(N=CN=C2Cl)N1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1 Chemical compound O=C1NC2=C(N=CN=C2Cl)N1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)O)CC2)C=C1 FBASOTSZQWXLEH-HAQNSBGRSA-N 0.000 description 3
- UCJVWNUJBRCDSK-JOCQHMNTSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3/C=N\C4=C(O)N=CN=C43)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3/C=N\C4=C(O)N=CN=C43)C=C2)CC1 UCJVWNUJBRCDSK-JOCQHMNTSA-N 0.000 description 3
- ZHVHWRALJHSPQM-HDJSIYSDSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3/C=N\C4=CN=CN=C43)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3/C=N\C4=CN=CN=C43)C=C2)CC1 ZHVHWRALJHSPQM-HDJSIYSDSA-N 0.000 description 3
- YXXDOLDCQBZPSP-QAQDUYKDSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(C4=CC=CC=C4)=NC4=C3N=CN=C4Cl)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(C4=CC=CC=C4)=NC4=C3N=CN=C4Cl)C=C2)CC1 YXXDOLDCQBZPSP-QAQDUYKDSA-N 0.000 description 3
- LEPJAKXCVUUKRZ-HDJSIYSDSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(C4CC4)=NC4=C3N=CN=C4Cl)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C(C4CC4)=NC4=C3N=CN=C4Cl)C=C2)CC1 LEPJAKXCVUUKRZ-HDJSIYSDSA-N 0.000 description 3
- JQNDCIFORLMANV-JOCQHMNTSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C(Cl)N=CN=C43)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C(Cl)N=CN=C43)C=C2)CC1 JQNDCIFORLMANV-JOCQHMNTSA-N 0.000 description 3
- KNLKSIHMPXBWKQ-IYARVYRRSA-N O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4C3=CC=CC=C3)C=C2)CC1 Chemical compound O=P(O)(O)C[C@H]1CC[C@H](C2=CC=C(N3C=NC4=C3N=CN=C4C3=CC=CC=C3)C=C2)CC1 KNLKSIHMPXBWKQ-IYARVYRRSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 208000011661 metabolic syndrome X Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- SYJWNXOLUSJISI-UHFFFAOYSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2COP(=O)(O)OC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2COP(=O)(O)OC2)C=C1 SYJWNXOLUSJISI-UHFFFAOYSA-N 0.000 description 2
- QVZDQNCEAFRUNM-WKILWMFISA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3CC3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3CC3)CC2)C=C1 QVZDQNCEAFRUNM-WKILWMFISA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- 101500016415 Lophius americanus Glucagon-like peptide 1 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100029795 Sodium-dependent glucose transporter 1 Human genes 0.000 description 2
- 101710181093 Sodium-dependent glucose transporter 1 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000005354 acylalkyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001539 anorectic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960002701 liraglutide Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229960003611 pramlintide Drugs 0.000 description 2
- 108010029667 pramlintide Proteins 0.000 description 2
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- AXEFIGHWTZPXOH-DLGLCQKISA-N (+-)-7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid Chemical compound C1N(C2)CN3CN1CN2C3.C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C AXEFIGHWTZPXOH-DLGLCQKISA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 108700021677 Agouti-Related Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- LFSZNGOOVJKHSO-UHFFFAOYSA-N CC(C)(CO)COP(=O)(O)C1=CC=C(NC(=O)NC2=CC=CC=C2)C=C1 Chemical compound CC(C)(CO)COP(=O)(O)C1=CC=C(NC(=O)NC2=CC=CC=C2)C=C1 LFSZNGOOVJKHSO-UHFFFAOYSA-N 0.000 description 1
- NOUFQGACSFKGDE-UAPYVXQJSA-N CC(C)COP(=O)(O)O[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CC(C)COP(=O)(O)O[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 NOUFQGACSFKGDE-UAPYVXQJSA-N 0.000 description 1
- VDBFQIBFZDHQKO-QAQDUYKDSA-N CC(C)P(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CC(C)P(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 VDBFQIBFZDHQKO-QAQDUYKDSA-N 0.000 description 1
- ZUWBVIPVUZEXOK-UHFFFAOYSA-N CC.CC.CC.COP(=O)(C[W])C(C)([Rb])[RaH].COP(=O)(C[W])C([Rb])([RaH])N1CCN(C2=CC=C(C)C=C2)CC1.COP(=O)(C[W])C([Rb])([RaH])N1CCN(C2=CC=CC=C2)CC1.[H]N1CCN(C2=CC=CC=C2)CC1 Chemical compound CC.CC.CC.COP(=O)(C[W])C(C)([Rb])[RaH].COP(=O)(C[W])C([Rb])([RaH])N1CCN(C2=CC=C(C)C=C2)CC1.COP(=O)(C[W])C([Rb])([RaH])N1CCN(C2=CC=CC=C2)CC1.[H]N1CCN(C2=CC=CC=C2)CC1 ZUWBVIPVUZEXOK-UHFFFAOYSA-N 0.000 description 1
- XFHPJYLJNOGDFL-WZDAETOFSA-N CC.CC.CC[W].COP(=O)(C[W])C[C@H]1CC[C@H](C2=CC=C(C)C=C2)CC1.COP(C)(=O)C[W].COP(C)(C)=O.[H]C[C@H]1CC[C@H](C2=CC=C(C)C=C2)CC1.[H]P(C)(=O)OC Chemical compound CC.CC.CC[W].COP(=O)(C[W])C[C@H]1CC[C@H](C2=CC=C(C)C=C2)CC1.COP(C)(=O)C[W].COP(C)(C)=O.[H]C[C@H]1CC[C@H](C2=CC=C(C)C=C2)CC1.[H]P(C)(=O)OC XFHPJYLJNOGDFL-WZDAETOFSA-N 0.000 description 1
- NZYCTVWQFQIRJY-KOMQPUFPSA-N CC1(C)OC2=C(N=C1C1=CC=C([C@H]3CC[C@H](P(C)(=O)O)CC3)C=C1)C(N)=NC=N2 Chemical compound CC1(C)OC2=C(N=C1C1=CC=C([C@H]3CC[C@H](P(C)(=O)O)CC3)C=C1)C(N)=NC=N2 NZYCTVWQFQIRJY-KOMQPUFPSA-N 0.000 description 1
- FFYPMUCTDLUYOY-UHFFFAOYSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2CCC(OP(=O)(O)CC3=CC=CC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2CCC(OP(=O)(O)CC3=CC=CC=C3)CC2)C=C1 FFYPMUCTDLUYOY-UHFFFAOYSA-N 0.000 description 1
- VNWKGRLLCCQJCV-UHFFFAOYSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2CCC(OP(=O)(O)OC3CCCC3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C(C2CCC(OP(=O)(O)OC3CCCC3)CC2)C=C1 VNWKGRLLCCQJCV-UHFFFAOYSA-N 0.000 description 1
- WRUJCYILCOHMKV-HCGLCNNCSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC(CN4CCOCC4)=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC(CN4CCOCC4)=C3)CC2)C=C1 WRUJCYILCOHMKV-HCGLCNNCSA-N 0.000 description 1
- XWVJKJNQYCRIPP-IYARVYRRSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC(Cl)=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC(Cl)=C3)CC2)C=C1 XWVJKJNQYCRIPP-IYARVYRRSA-N 0.000 description 1
- ILEZLGBQAUUSBX-WGSAOQKQSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CC=C3)CC2)C=C1 ILEZLGBQAUUSBX-WGSAOQKQSA-N 0.000 description 1
- MQEBZWYOIACKIV-QAQDUYKDSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CS3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CC=CS3)CC2)C=C1 MQEBZWYOIACKIV-QAQDUYKDSA-N 0.000 description 1
- OEDYVTJYICJGOF-QAQDUYKDSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CSC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3=CSC=C3)CC2)C=C1 OEDYVTJYICJGOF-QAQDUYKDSA-N 0.000 description 1
- RKXAJGOPIJLZFR-IYARVYRRSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3CCCC3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)C3CCCC3)CC2)C=C1 RKXAJGOPIJLZFR-IYARVYRRSA-N 0.000 description 1
- LWPFWSYEXJANAL-HZCBDIJESA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)CCC3=CC=CC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(=O)(O)CCC3=CC=CC=C3)CC2)C=C1 LWPFWSYEXJANAL-HZCBDIJESA-N 0.000 description 1
- RVVOTGHRSPJRBM-SHTZXODSSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(C)(=O)O)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](CP(C)(=O)O)CC2)C=C1 RVVOTGHRSPJRBM-SHTZXODSSA-N 0.000 description 1
- KPJKBUDXBSKPAJ-KESTWPANSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CC=CC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CC=CC=C3)CC2)C=C1 KPJKBUDXBSKPAJ-KESTWPANSA-N 0.000 description 1
- ASTZKKOHTKIFKX-SAABIXHNSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CC=CS3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CC=CS3)CC2)C=C1 ASTZKKOHTKIFKX-SAABIXHNSA-N 0.000 description 1
- IYRMHXVGXZPTSG-SAABIXHNSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CSC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)C3=CSC=C3)CC2)C=C1 IYRMHXVGXZPTSG-SAABIXHNSA-N 0.000 description 1
- TVSMEKQKYSLRLS-XYWHTSSQSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)CC3=CC=C(C(=O)O)C=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)CC3=CC=C(C(=O)O)C=C3)CC2)C=C1 TVSMEKQKYSLRLS-XYWHTSSQSA-N 0.000 description 1
- CDVBFMVKVYLCKE-CTYIDZIISA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)O)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)O)CC2)C=C1 CDVBFMVKVYLCKE-CTYIDZIISA-N 0.000 description 1
- FMXLNCHAMHQPRE-XUTJKUGGSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCC3=CC=CN=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCC3=CC=CN=C3)CC2)C=C1 FMXLNCHAMHQPRE-XUTJKUGGSA-N 0.000 description 1
- DSXFLHZKXBEWAN-XUTJKUGGSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCC3=CC=NC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCC3=CC=NC=C3)CC2)C=C1 DSXFLHZKXBEWAN-XUTJKUGGSA-N 0.000 description 1
- QQFCDTBBIHQRKM-AFARHQOCSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCCC3=CC=CC=C3)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)(O)OCCC3=CC=CC=C3)CC2)C=C1 QQFCDTBBIHQRKM-AFARHQOCSA-N 0.000 description 1
- RFGCPHMVOPOOSW-XYWHTSSQSA-L CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)([O-])CC3=CC=CC(C(=O)[O-])=C3)CC2)C=C1.[Na+].[Na+] Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(=O)([O-])CC3=CC=CC(C(=O)[O-])=C3)CC2)C=C1.[Na+].[Na+] RFGCPHMVOPOOSW-XYWHTSSQSA-L 0.000 description 1
- LDCBRYNCGJGABT-KOMQPUFPSA-N CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(C)(=O)O)CC2)C=C1 Chemical compound CC1(C)OC2=NC=NC(N)=C2N=C1C1=CC=C([C@H]2CC[C@H](OP(C)(=O)O)CC2)C=C1 LDCBRYNCGJGABT-KOMQPUFPSA-N 0.000 description 1
- SVFNKSISHSUYQS-IYARVYRRSA-N CCCCP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CCCCP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 SVFNKSISHSUYQS-IYARVYRRSA-N 0.000 description 1
- XTIWIZBKBJEYBS-UHFFFAOYSA-N CCOP(=O)(O)OC1CCC(C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CCOP(=O)(O)OC1CCC(C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 XTIWIZBKBJEYBS-UHFFFAOYSA-N 0.000 description 1
- CUGJHKWWFGVRPL-WKILWMFISA-N CCP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CCP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 CUGJHKWWFGVRPL-WKILWMFISA-N 0.000 description 1
- WYPWRLBZONOGQE-JCNLHEQBSA-N CCP(=O)(O)O[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 Chemical compound CCP(=O)(O)O[C@H]1CC[C@H](C2=CC=C(C3=NC4=C(N)N=CN=C4OC3(C)C)C=C2)CC1 WYPWRLBZONOGQE-JCNLHEQBSA-N 0.000 description 1
- KXNBPLFFNSHDGU-MXVIHJGJSA-N CN(C)C1=CC=C(P(=O)(O)C[C@H]2CC[C@H](C3=CC=C(C4=NC5=C(N)N=CN=C5OC4(C)C)C=C3)CC2)C=C1.[Br-].[H][N+]([H])([H])[H] Chemical compound CN(C)C1=CC=C(P(=O)(O)C[C@H]2CC[C@H](C3=CC=C(C4=NC5=C(N)N=CN=C5OC4(C)C)C=C3)CC2)C=C1.[Br-].[H][N+]([H])([H])[H] KXNBPLFFNSHDGU-MXVIHJGJSA-N 0.000 description 1
- AJSFVEMVSLUOGH-SHTZXODSSA-N CP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(NC(=O)C3=NN=C(NC4=CC=C(F)C(F)=C4)O3)C=C2)CC1 Chemical compound CP(=O)(O)C[C@H]1CC[C@H](C2=CC=C(NC(=O)C3=NN=C(NC4=CC=C(F)C(F)=C4)O3)C=C2)CC1 AJSFVEMVSLUOGH-SHTZXODSSA-N 0.000 description 1
- QJJHNUQDSBHINT-DNQXCXABSA-N CP(=O)(O)[C@@H]1CCC[C@H]1C(=O)C1=CC=C(C2=CC=C(NC(=O)NC3=CC=CC=C3)C=C2)C=C1 Chemical compound CP(=O)(O)[C@@H]1CCC[C@H]1C(=O)C1=CC=C(C2=CC=C(NC(=O)NC3=CC=CC=C3)C=C2)C=C1 QJJHNUQDSBHINT-DNQXCXABSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 description 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 description 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 description 1
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 description 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 1
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 1
- 102000001796 Melanocortin 4 receptors Human genes 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZWJAGDQXHVCRJX-UHFFFAOYSA-M O=C(NC1=CC=CC=C1)NC1=CC=C(C2=CC=C(C3CCOP(=O)([O-])O3)C=C2)C=C1.[Na+] Chemical compound O=C(NC1=CC=CC=C1)NC1=CC=C(C2=CC=C(C3CCOP(=O)([O-])O3)C=C2)C=C1.[Na+] ZWJAGDQXHVCRJX-UHFFFAOYSA-M 0.000 description 1
- BOOXNNGKZPYXMA-QAQDUYKDSA-N OC(C(F)(F)[F]c(nc1Nc2ccccc2)nc2c1nc[n]2-c1ccc([C@H]2CC[C@H](CP(O)(O)=O)CC2)cc1)=O Chemical compound OC(C(F)(F)[F]c(nc1Nc2ccccc2)nc2c1nc[n]2-c1ccc([C@H]2CC[C@H](CP(O)(O)=O)CC2)cc1)=O BOOXNNGKZPYXMA-QAQDUYKDSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229940127347 Serotonin 2c Receptor Agonists Drugs 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- DAYKLWSKQJBGCS-NRFANRHFSA-N aleglitazar Chemical compound C1=2C=CSC=2C(C[C@H](OC)C(O)=O)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 DAYKLWSKQJBGCS-NRFANRHFSA-N 0.000 description 1
- 229950010157 aleglitazar Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003576 central nervous system agent Substances 0.000 description 1
- 229940125693 central nervous system agent Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CNKJPHSEFDPYDB-HSJNEKGZSA-N decanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CNKJPHSEFDPYDB-HSJNEKGZSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical class C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical class C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3229—Esters of aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65306—Five-membered rings containing two nitrogen atoms
- C07F9/65312—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Definitions
- Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI >30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the rise.
- therapies orlistat, sibutramine
- sub-optimal efficacy only 5-10% weight loss when used in combination with diet and exercise plans
- poor tolerability profiles More recently, Sanofi Aventis' CB1 receptor antagonist, rimonabant, was withdrawn from the market due to adverse psychiatric side effects. The success of future obesity treatments will depend on their ability to elicit sustained and robust weight loss with improved safety/tolerability profiles.
- Obesity (BMI >30) is the long term consequence of an imbalance between energy intake and energy expenditure (Hill et al., 2000). Further, obesity is associated with decreased life span due to numerous co-morbidities that include coronary artery disease, hypertension, stroke, diabetes, hyperlipidemia, osteoarthritis and some cancers. Adiposity is a hallmark of obesity that results from the excessive deposition of the energy storage molecule triacylglycerol (TAG) in all tissues as well as an increase in overall adipose tissue mass due to increased adipocyte size and number.
- TAG triacylglycerol
- DGAT-1 diacylglycerol O-acyltransferase 1
- DGATs are membrane-bound enzymes that catalyze the terminal step of TAG biosynthesis (Yen et al., 2008).
- DAG diacylglycerol
- the DGAT-1 and DGAT-2 enzymes have no significant protein sequence homology.
- DGAT-1 has also been shown to catalyze the acylation of monoacylglycerol to form DAG (Yen et al., 2005).
- DGAT-1 and DGAT-2 null mice have been generated and extensively characterized (Smith et al., 2000; Stone et al., 2004).
- DGAT-2 null mice are lipopenic and die soon after birth from reductions in substrates for energy metabolism and from impaired permeability barrier function.
- DGAT-1 mice are fertile and viable with a normal life span and do not become obese when fed a TAG rich diet.
- DGAT-1 null mice exhibit both reduced postprandial plasma TAG levels and increased energy expenditure, but have normal levels of circulating free fatty acids.
- transgenic mice that over-express DGAT-1 in adipose tissue are predisposed to obesity when fed a TAG rich diet and have elevated levels of circulating free fatty acids (Chen et al., 2002).
- DGAT-1 is highly expressed in several tissue types that are relevant to obesity, such as intestine, liver and adipose (Yen et al., 2008). Further, DGAT-1 is predominantly localized to the lumen of the endoplasmic reticulum (Yamazaki et al., 2005). Thus, there are several sites of action for a DGAT-1 inhibitor that can lead to both a reduction in adiposity and body weight. First, blocking DGAT-1 activity in the intestine or liver will inhibit the export of chylomicron and VLDL particles, respectively, thereby reducing peripheral TAG deposition that originates either from dietary TAG re-esterification or from de novo lipogenesis.
- DGAT-1 inhibition may also generate a peripheral satiety signal resulting in an anorexigenic effect.
- the in vivo pharmacology of a potent orally bioavailable DGAT-1 inhibitor was disclosed (Zhao et al., 2008). Proof of concept studies in rodent models of obesity with this inhibitor demonstrated target engagement, weight loss and reductions in adiposity. This inhibitor showed high oral bioavailability and high systemic exposure.
- High systemic exposure of a DGAT-1 inhibitor can potentially result in undesirable side effects such as reduced lactation in nursing females, reduced sebum production, and exacerbation of myocardial injury during ischemia.
- human milk TAGs are a major source of nutrition to the nursing infant and systemic inhibition of DGAT-1 would reduce milk TAG production.
- Female DGAT-1 null mice are unable to nurse their pups due to reduced lactation.
- Triglycerides are also a major component of human sebum, which is an important skin lubricant.
- Systemic inhibition of DGAT-1 would reduce sebum production and may result in skin and hair disorders as observed in DGAT-1 null mice.
- the systemic inhibition of DGAT-1 could substantially increase free fatty acid availability and utilization by the heart. During ischemia, the utilization of a less efficient fuel source such as fatty acids rather than glucose may enhance myocardial injury.
- DGAT-1 inhibitors One approach to improve the therapeutic index of DGAT-1 inhibitors is to exclusively target DGAT-1 expressed in the enterocyte by restricting drug exposure primarily to enterocytes. DGAT-1 inhibitors with low systemic exposure and good oral bioavailability specifically targeted to enterocytes would avoid safety issues potentially associated with compounds that reach high levels in the systemic circulation.
- the invention pertains to use of DGAT-1 inhibitors to treat and/or prevent overweight, obesity and the dyslipidemia associated with it. Because of the mechanism and specific targeting to enterocytes of the DGAT-1 inhibitors of the invention, other conditions also can be ameliorated, reduced or avoided. These conditions include high postprandial triglycerides (very common in diabetes) or diet- or obesity-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance and glucose intolerance (e.g., improved insulin sensitivity due to reduced deposition of liver and skeletal muscle fat) seen in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X, polycystic ovary or other disorders.
- high postprandial triglycerides very common in diabetes
- diet- or obesity-related hypertriglyceridemia cardiovascular risk associated with excessive triglycerides
- insulin resistance and glucose intolerance e.g., improved insulin sensitivity due to reduced deposition of liver and skeletal muscle fat
- the DGAT-1 inhibitor compounds and compositions disclosed herein primarily target enterocytes lining the intestinal walls.
- the disclosed compounds can be administered orally and are taken up readily into enterocytes; however, compounds of the invention are not readily exported from the enterocytes into the systemic circulation. This results in low systemic exposure to the compounds disclosed herein and reduced risk of systemic side effects associated with general systemic DGAT-1 inhibition.
- alkyl refers to a straight or branched or cyclic chain hydrocarbon radical with only single carbon-carbon bonds. Representative examples include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, cyclobutyl, pentyl, cyclopentyl, hexyl, and cyclohexyl, all of which may be optionally substituted.
- Alkyl groups are C 1 -C 12 and include alkyl groups that are C 1 -C 8 in some embodiments.
- aryl refers to aromatic groups which have 5-14 ring atoms and at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
- Carbocyclic aryl groups are groups which have, in various embodiments, 6-10 or 6-14 ring atoms wherein the ring atoms on the aromatic ring are carbon atoms.
- Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as optionally substituted naphthyl groups.
- Heterocyclic aryl or heteroaryl groups are groups which have, in vanous embodiments, 5-10 or 5-14 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms.
- Suitable heteroatoms include oxygen, sulfur, nitrogen, and selenium.
- Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, and the like, all optionally substituted.
- biasing represents aryl groups which have 5-14 atoms containing more than one aromatic ring including both fused ring systems and aryl groups substituted with other aryl groups. Such groups may be optionally substituted. Suitable biaryl groups include naphthyl and biphenyl.
- optionally substituted or “substituted” includes groups substituted by one to six substituents, independently selected from lower alkyl, lower aryl, lower aralkyl, lower cyclic alkyl, lower heterocycloalkyl, hydroxy, lower alkoxy, lower aryloxy, perhaloalkoxy, aralkoxy, lower heteroaryl, lower heteroaryloxy, lower heteroarylalkyl, lower heteroaralkoxy, azido, amino, halo, lower alkylthio, oxo, lower acylalkyl, lower carboxy esters, carboxyl, -carboxamido, nitro, lower acyloxy, lower aminoalkyl, lower alkylaminoaryl, lower alkylaryl, lower alkylaminoalkyl, lower alkoxyaryl, lower arylamino, lower aralkylamino, sulfonyl, lower-carboxamidoalkylaryl, lower-carboxamido
- Substituted aryl and “substituted heteroaryl” refers to aryl and heteroaryl groups substituted with 1-3 substituents. These substituents are selected from the group consisting of lower alkyl, lower alkoxy, lower perhaloalkyl, halo, hydroxy, and amino.
- -aralkyl refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, and may be optionally substituted. “Heteroarylalkyl” refers to an alkylene group substituted with a heteroaryl group.
- alkylaryl- refers to an aryl group substituted with an alkyl group. “Lower alkylaryl-” refers to such groups where alkyl is lower alkyl.
- lower referred to herein in connection with organic radicals or compounds respectively defines such as with up to and including 10, in one aspect up to and including 6, and in another aspect one to four carbon atoms.
- Such groups may be straight chain, branched, or cyclic.
- cyclic alkyl or “cycloalkyl” refers to alkyl groups that are cyclic of 3 to 10 carbon atoms, and in one aspect are 3 to 6 or 3 to 8 carbon atoms. Suitable cyclic groups include norbornyl and cyclopropyl. Such groups may be substituted.
- heterocyclic refers to cyclic groups of 3 to 10 atoms, and in one aspect are 3 to 6 atoms, containing at least one heteroatom, in a further aspect are 1 to 3 heteroatoms.
- Suitable heteroatoms include oxygen, sulfur, and nitrogen.
- Heterocyclic groups may be attached through a nitrogen or through a carbon atom in the ring.
- the heterocyclic alkyl groups include unsaturated cyclic, fused cyclic and spirocyclic groups.
- Suitable heterocyclic groups include pyrrolidinyl, morpholino, morpholinoethyl, and pyridyl.
- arylamino (a), and “aralkylamino” (b), respectively, refer to the group —NRR′ wherein respectively, (a) R is aryl and R′ is hydrogen, alkyl, aralkyl, heterocycloalkyl, or aryl, and (b) R is aralkyl and R′ is hydrogen, aralkyl, aryl, alkyl or heterocycloalkyl.
- acyl refers to —C(O)R where R is alkyl, heterocycloalkyl, or aryl.
- carboxy esters refers to —C(O)OR where R is alkyl, aryl, aralkyl, cyclic alkyl, or heterocycloalkyl, all optionally substituted.
- oxo refers to ⁇ O in an alkyl or heterocycloalkyl group.
- amino refers to —NRR′ where R and R′ are independently selected from hydrogen, alkyl, aryl, aralkyl and heterocycloalkyl, all except H are optionally substituted; and R and R′ can form a cyclic ring system.
- -sulphonylamido or “-sulfonylamido” refers to —S( ⁇ O) 2 NR 2 where each R is independently hydrogen or alkyl.
- halogen refers to —F, —Cl, —Br and —I.
- alkylaminoalkylcarboxy refers to the group alkyl-NR-alk-C(O)—O— where “alk” is an alkylene group, and R is an H or lower alkyl.
- sulphonyl or “sulfonyl” refers to —SO 2 R, where R is H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- sulphonate or “sulfonate” refers to —SO 2 OR, where R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- alkenyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon double bond and includes straight-chain, branched-chain and cyclic groups. Alkenyl groups may be optionally substituted. Suitable alkenyl groups include allyl. “1-alkenyl” refers to alkenyl groups where the double bond is between the first and second carbon atom. If the 1-alkenyl group is attached to another group, e.g., it is a W substituent attached to the cyclic phosphonate, it is attached at the first carbon.
- alkynyl refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon triple bond and includes straight-chain, branched-chain and cyclic groups. Alkynyl groups may be optionally substituted. Suitable alkynyl groups include ethynyl. “1-alkynyl” refers to alkynyl groups where the triple bond is between the first and second carbon atom. If the 1-alkynyl group is attached to another group, e.g., it is a W substituent attached to the cyclic phosphonate, it is attached at the first carbon.
- alkylene refers to a divalent straight chain, branched chain or cyclic saturated aliphatic group. In one aspect the alkylene group contains up to and including 10 atoms. In another aspect the alkylene chain contains up to and including 6 atoms. In a further aspect the alkylene groups contains up to and including 4 atoms. The alkylene group can be either straight, branched or cyclic.
- acyloxy refers to the ester group —O—C(O)R, where R is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, or heterocycloalkyl.
- aminoalkyl- refers to the group NRralk- wherein “alk” is an alkylene group and R is selected from —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- alkylaminoalkyl- refers to the group alkyl-NR-alk- wherein each “alk” is an independently selected alkylene, and R is H or lower alkyl. “Lower alkylaminoalkyl-” refers to groups where the alkyl and the alkylene group is lower alkyl and alkylene, respectively.
- arylaminoalkyl- refers to the group aryl-NR-alk- wherein “alk” is an alkylene group and R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- alkylene group is lower alkylene.
- alkylaminoaryl- refers to the group alkyl-NR-aryl- wherein “aryl” is a divalent group and R is —H, alkyl, aralkyl, or heterocycloalkyl. In “lower alkylaminoaryl-”, the alkyl group is lower alkyl.
- alkoxyaryl- refers to an aryl group substituted with an alkyloxy group.
- the alkyl group is lower alkyl.
- aryloxyalkyl- refers to an alkyl group substituted with an aryloxy group.
- aralkyloxyalkyl- refers to the group aryl-alk-O-alk- wherein “alk” is an alkylene group. “Lower aralkyloxyalkyl-” refers to such groups where the alkylene groups are lower alkylene.
- alkoxy- or “alkyloxy-” refers to the group alkyl-O—.
- alkoxyalkyl- or “alkyloxyalkyl-” refers to the group alkyl-O-alk- wherein “alk” is an alkylene group. In “lower alkoxyalkyl-”, each alkyl and alkylene is lower alkyl and alkylene, respectively.
- alkylthio- and “alkylthio-” refer to the group alkyl-S—.
- alkylthioalkyl- refers to the group alkyl-S-alk- wherein “alk” is an alkylene group.
- alk is an alkylene group.
- lower alkylthioalkyl- each alkyl and alkylene is lower alkyl and alkylene, respectively.
- alkoxycarbonyloxy- refers to alkyl-O—C(O)—O—.
- aryloxycarbonyloxy- refers to aryl-O—C(O)—O—.
- alkylthiocarbonyloxy- refers to alkyl-S—C(O)—O—.
- amido refers to the NR 2 group next to an acyl or sulfonyl group as in NR 2 —C(O)—, RC(O)—NR 1 —, NR 2 —S( ⁇ O) 2 — and RS( ⁇ O) 2 NR 1 —, where R and R 1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- Carboxamido refers to NR 2 —C(O)— and RC(O)—NR 1 —, where R and R 1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl. The term does not include urea, —NR—C(O)—NR—.
- sulphonamido or “sulfonamido” refer to NR 2 —S( ⁇ O) 2 — and RS( ⁇ O) 2 —NR 1 —, where R and R 1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl. The term does not include sulfonylurea, —NR—S( ⁇ O) 2 NR—.
- carboxamidoalkylaryl and “carboxamidoaryl” refer to an aryl-alk-NR 1 —C(O), and ar-NR 1 —C(O)-alk-, respectively where “ar” is aryl, “alk” is alkylene, R 1 and R include H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- sulfonamidoalkylaryl and “sulfonamidoaryl” refer to an aryl-alk-NR 1 —S( ⁇ O)r, and ar-NR 1 —S( ⁇ O) 2 , respectively where “ar” is aryl, “alk” is alkylene, R 1 and R include —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- hydroxyalkyl refers to an alkyl group substituted with one —OH.
- haloalkyl refers to an alkyl group substituted with one halo.
- cyano refers to —C ⁇ N.
- nitro refers to —NO 2 .
- acylalkyl refers to an alkyl-C(O)-alk-, where “alk” is alkylene.
- aminocarboxamidoalkyl- refers to the group NR 2 —C(O)—N(R)-alk- wherein R is an alkyl group or Hand “alk” is an alkylene group. “Lower aminocarboxamidoalkyl-” refers to such groups wherein “alk” is lower alkylene.
- heteroarylalkyl refers to an alkylene group substituted with a heteroaryl group.
- perhalo refers to groups wherein every C—H bond has been replaced with a C-halo bond on an aliphatic or aryl group.
- Suitable perhaloalkyl groups include —CF 3 and —CFCl 2 .
- carboxylic acid moiety refers to a compound having a carboxylic acid group (—COOR), and salts thereof, a carboxylic acid ester, or a carboxylic acid surrogate.
- Suitable carboxylic acid surrogates include a tetrazole group, a hydroxamic acid group, a thiazolidinedione group, an acylsulfonamide group, and a 6-azauracil. (see, e.g., The Practice of ⁇ vfedicinal Chemistry ; Wemuth, C. G., Ed.; Academic Press: New York, 1996; p. 203).
- terapéuticaally effective amount means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
- patient means an animal.
- animal includes birds and mammals, in one embodiment a mammal, including a dog, cat, cow, horse, goat, sheep, pig or human. In one embodiment the animal is a human. In another embodiment the animal is a male. In another embodiment the animal is a female.
- hypocholesterolemia refers to presence of an abnormally large amount of cholesterol in the cells and plasma of the circulating blood.
- hypolipidemia or “lipemia” refers to the presence of an abnormally large amount of lipids in the circulating blood.
- Atherosclerosis refers to a condition characterized by irregularly distributed lipid deposits in the intima of large and medium-sized arteries wherein such deposits provoke fibrosis and calcification. Atherosclerosis raises the risk of angina, stroke, heart attack, or other cardiac or cardiovascular conditions.
- obese refers to the condition of being obese. Being obese is defined as a BMI of 30.0 or greater; and extreme obesity is defined at a BMI of 40 or greater.
- BMI bodyMI
- Overweight is defined as a body mass index of 25.0 to 29.9. (This is generally about 10 percent over an ideal body weight.)
- IGT impaired glucose tolerance
- insulin resistance is defined clinically as the impaired ability of a known quantity of exogenous or endogenous insulin to increase whole body glucose uptake and utilization.
- insulin regulates a wide variety of metabolic processes in addition to glucose homeostasis e.g., lipid and protein metabolism
- the manifestations of insulin resistance are diverse and include one or more of the following: glucose intolerance, hyperinsulinemia, a characteristic dyslipidemia (high triglycerides; low high-density lipoprotein cholesterol, and small, dense low-density lipoprotein cholesterol), obesity, upper-body fat distribution, fat accumulation in the liver (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), increased hepatic glucose output, reduced hepatic glucose uptake and storage into glycogen, hypertension, and increased prothrombotic and antifibrinolytic factors.
- This cluster of cardiovascular-metabolic abnormalities is commonly referred to as “The Insulin Resistance Syndrome” or “The Metabolic Syndrome” and may lead to the development of
- Metalabolic Syndrome or “Metabolic Syndrome X” is characterized by a group of metabolic risk factors in one person. They include:
- Metal Syndrome or “Metabolic Syndrome X” is identified by the presence of three or more of these components:
- metabolic disease includes diseases and conditions such as obesity, diabetes and lipid disorders such as hypercholesterolemia, hyperlipidemia, hypertriglyceridemia as well as disorders that are associated with abnormal levels of lipoproteins, lipids, carbohydrates and insulin such as metabolic syndrome X, diabetes, impaired glucose tolerance, atherosclerosis, coronary heart disease, cardiovascular disease.
- diseases and conditions such as obesity, diabetes and lipid disorders such as hypercholesterolemia, hyperlipidemia, hypertriglyceridemia as well as disorders that are associated with abnormal levels of lipoproteins, lipids, carbohydrates and insulin such as metabolic syndrome X, diabetes, impaired glucose tolerance, atherosclerosis, coronary heart disease, cardiovascular disease.
- the term “significant” or “statistically significant” means a result (i.e. experimental assay result) where the p-value is ⁇ 0.05 (i.e. the chance of a type I error is less than 5%) as determined by an art-accepted measure of statistical significance appropriate to the experimental design.
- the present invention provides compounds that are useful for treating or preventing conditions and disorders associated with DGAT in mammals, particularly humans.
- One aspect of the invention is directed towards the compounds represented by Formula (I), pharmaceutically acceptable salts or stereoisomers thereof, Q-G 1 -G 2 -G 3 -G 4 -Z Formula(I) wherein Q is Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , Q 8 , or Q 9 , as defined herein and for each of Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , Q 8 , or Q 9 , common substituents found in the structures are defined as follows: R 1 is selected from the group consisting of H, (C 1 -C 8 )alkyl, halo(C 1 -C 4 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, C(O)R
- J is selected from —NR a R b or —OR a ;
- X is selected from the group consisting of C(R 4 ) and N; optionally, when X is C(R 4 ), R a or R b may be combined with R 4 or R 4 may be combined with R 1 to form a 5-, 6- or 7-membered fused ring;
- E is selected from the group consisting of 0 and S;
- Q 2 is
- R 5 is H or (C 1 -C 4 )alkyl
- X is N or C(R 4 ) and when X is C(R 4 ), R 4 may be combined with R 1 to form a 5-, 6- or 7-membered fused ring
- R 2 and R 3 are as defined above or may be combined with R 5 to form a 3-, 4-, 5- or 6-membered spiro ring; optionally, having from 0 to 3 heteroatoms selected from the group consisting of N, O and S;
- Q 3 is
- Q 6 is R 7 (V) n C(O)(NH) m —;
- R 7 is (C 1 -C 8 )alkyl, aryl, heteroaryl or (C 3 -C 8 )cycloalkyl; wherein each of the aryl, heteroaryl and cycloalkyl is independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of (C 1 -C 8 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, —CN, halogen, ethylenedioxy, methylenedioxy, haloalkyl, —OR a , —O—C(O)(R a ), —S(R a ), —S(O)(R b ), —S(O) 2 (R b ), —C(O)(R a ), —C(O)(OR a ), —
- D is O, NW, or S; and A is a fused ring selected from an aromatic 6-membered ring containing 0 or 2 N atoms; the number of R 8 substituents on A ring may be 0, 1 or 2 and when two of said R 8 substituents are: a) found on A ring; b) (C 1 -C 6 )alkyl and c) attached to adjacent carbon atoms of the Ring A, they may be joined together to form a 5 to 7-membered carbocyclic ring; and RC is H or (C 1 -C 6 )alkyl, hydroxyl(C 2 -C 6 )alkyl; Q 8 ⁇ is
- L is N or C(R 8 ); and the number of R 8 substituents on A ring may be 0, 1, 2 or 3 and when two of said R 8 substituents are: a) found on A ring; b) (C 1 -C 6 )alkyl and c) attached to adjacent carbon atoms of the Ring A, they may be joined together to form a 5- to 7-membered carbocyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N, S; or Q 9 is a [5,5], [5,6], [6,5] and [6,6] bicyclic heterocycle containing 1 to 4 N atoms where G 1 is connected through one of the ring N atoms; G 1 and G 3 are independently selected from the group consisting of cyclo(C 3 -C 8 )alkylene, heterocyclo(C 3 -C 8 )alkylene, arylene and heteroarylene, optionally substituted with one or two groups independently selected from halo, (C 1 -C 6 )
- G2 is selected from the group consisting of a bond, (C 1 -C 4 )alkylene, (C 2 -C 4 )alkenylene, O, N(R 3 )C(O), S and S(O) 2 ;
- G4 is —X—Y wherein X is selected from null, O, NH, CO, CHOH, S or S(O) 2 ; and Y is selected from (C 1 -C 4 )alkylene, (C 3 -C 8 )-cycloalkylene or (C 3 -C 8 )-heterocycloalkylene, —CH(R 9 )C(R 10 R 11 )— or —N(R 9 )C(R 10 R 11 )— wherein R 10 and R 11 are both hydrogen, and R 9 is hydrogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, (C 2 -C 6 )alkenyl, phenoxy-(C 2
- X 1 and X 2 are independently selected from null, (C(R a R b )) n , O, NR a , S or CO and n is 0 or 1; W is selected from H, (C 1 -C 6 )alkyl, aryl, heteroaryl or (C 3 -C 8 )cycloalkyl; wherein each of the alkyl, aryl, heteroaryl and cycloalkyl is independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 2 -C 8 )alkenyl, (C 2 -C 8 )alkynyl, —CN, halogen, ethylenedioxy, methylenedioxy, haloalkyl, —Or a , —O—C(O)(R a ), —S(R a ), —S(O)(R b ), —S(O)
- Another aspect of the invention provides for pharmaceutically acceptable salts of the compounds of Formula (I), in addition to those discussed in the definitions section of this application.
- Such salts include the conventional non-toxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
- such acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate persulfate, 3-phenylpropionate,
- Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine salts and N-methyl-D-glucamine Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides, and iodides; aralkyl halides like benzyl and phenethyl bromides and others.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlor
- compositions formed by combining the compounds of this invention with pharmaceutically acceptable carriers, vehicles or diluents. These pharmaceutically acceptable compositions can, then, be administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders and/or excipients.
- one aspect of the invention provides pharmaceutical composition for oral administration.
- tablets containing various excipients such as sodium citrate, calcium carbonate and/or calcium phosphate
- various disintegrants such as starch, alginic acid and/or certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and/or acacia.
- binding agents such as polyvinylpyrrolidone, sucrose, gelatin and/or acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
- Solid compositions comprising the aforementioned excipients, disintegrants and/or lubricating agents may also be employed as fillers in soft and hard filled gelatin capsules.
- materials such as lactose or milk sugar and high molecular weight polyethylene glycols can also be utilized in the preparation of soft or hard capsules disclosed herein.
- the active pharmaceutical agent therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and/or combinations thereof.
- Tablets and capsules disclosed herein can also be formulated with enteric coatings known to those skilled in the art.
- solutions comprising compounds disclosed herein can be formulated in oils (such as sesame or peanut oil), aqueous propylene glycol, or in sterile aqueous solutions.
- oils such as sesame or peanut oil
- aqueous propylene glycol or in sterile aqueous solutions.
- Aqueous solutions should be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- Compounds formulated as discussed herein are suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
- the compounds or compositions of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- the pressurized container or nebulizer may contain a solution or suspension of a compound of this invention.
- Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound or compounds of the invention and a suitable powder base such as lactose or starch.
- methods of inhibiting or reducing the activity of DGAT-1 in enterocytes comprise contacting an enterocyte with a composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I).
- the enterocyte is contacted with an amount of the composition sufficient to inhibit DGAT-1 activity within the cell. This method can be conducted in vitro or in vivo.
- treating includes palliating, slowing progression and/or reducing symptoms associated with a disease, such as obesity, insulin resistance syndrome, Type 2 diabetes, or adiposity.
- therapeutically effective amount means an amount of a compound of the present invention that (i) treats the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
- methods of treating a disease or condition amenable to treatment via DGAT-1 inhibition comprise administering to a mammal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt of the compound, either alone or in combination with an anti-diabetic agent as described above.
- Conditions that can be treated in this aspect of the invention include Type 2 diabetes, insulin resistance syndrome, obesity, impaired glucose tolerance, hyperglycemia, high postprandial triglycerides (very common in diabetes) or diet- or obesity-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance and glucose intolerance (e.g., improved insulin sensitivity due to reduced deposition of liver and skeletal muscle fat) seen in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X, polycystic ovary disease or other disorders such as diabetic complications that arise from obesity.
- Type 2 diabetes Type 2 diabetes, insulin resistance syndrome, obesity, impaired glucose tolerance, hyperglycemia, high postprandial triglycerides (very common in diabetes) or diet- or obesity-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance and glucose intolerance (e.g., improved insulin sensitivity due to reduced deposition of liver and skeletal muscle fat) seen in overweight patients, those
- the present invention also relates to therapeutic methods for treating the above described conditions in a mammal, including a human, wherein a compound of Formula (I) is administered as part of an appropriate dosage regimen designed to obtain the benefits of the therapy.
- a compound of Formula (I) is administered as part of an appropriate dosage regimen designed to obtain the benefits of the therapy.
- the appropriate dosage regimen, the amount of each dose administered and the intervals between doses of the compound will depend upon the compound of Formula (I) of this invention being used, the type of pharmaceutical compositions being used, the characteristics of the subject being treated and the severity of the conditions.
- an effective dosage for the compounds of the present invention is in the range of 0.01 mg/kg/day to 1000 mg/kg/day, preferably 0.01 mg/kg/day to 600 mg/kg/day of active compound (i.e., a compound of Formula (I)) in single or divided doses (for example, three doses of 200 mg/kg over the course of a day).
- active compound i.e., a compound of Formula (I)
- Some variation in dosage will necessarily occur, however, depending on the condition of the subject being treated.
- the individual responsible for dosing will, in any event, determine the appropriate dose for the individual subject. Practitioners will appreciate that “kg” refers to the weight of the subject measured in kilograms.
- the compounds or compositions of this invention may be administered in single (e.g., once daily) or multiple doses or via constant infusion.
- the compounds of this invention may also be administered alone or in combination with pharmaceutically acceptable carriers, vehicles or diluents, in either single or multiple doses.
- the compounds or compositions of the present invention may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally and parenterally, (e.g., intravenously or subcutaneously).
- the pharmaceutical compositions of this invention may be administered intranasally, as a suppository, or using a “flash” formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.
- the compounds are preferably delivered via a route that accesses the alimentary tract, e.g., orally or nasally.
- Combination therapies utilizing compounds of Formula (I) are provided by yet another aspect of the invention.
- compounds of Formula (I) can be administered in combination (concomitantly or sequentially and as a single combined composition or as separate compositions that are separately administered), with anti-diabetic and/or anti-obesity agents known to those skilled in the art.
- anti-obesity agents include: I) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (bupropion), selective serotonin 2c receptor agonists, antiseizure agents (topiramate, zonisamide), some dopamine antagonists, and cannabinoid-I receptor antagonists (rimonabant); 2) leptin/insulin/central nervous system pathway agents, including leptin analogues, leptin transport and/or leptin receptor promoters, ciliary neurotrophic factor (Axokine), neuropeptide Y and agouti-related peptide antagonists, proopiomelanocortin and ***e and amphetamine regulated transcript promoters, alpha-melanocyte-stimulating hormone analogues, melanocortin-4 receptor agonists, and agents that affect insulin metabolism/activity, which include protein-tyrosine phosphatase-IE inhibitors, peroxisome proliferator
- Anti-diabetic agents that can be used in the aforementioned combination therapies include, and are not limited to: insulin; sulfonylurea compounds, such as glyburide, tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glimepiride or gliclazide; meglitinides, such as repaglinide or nateglinide; biguanides, such as metformin, phenformin or buformin; thiazolidinediones, such as rosigliazone, pioglitozone or troglitazone, alpha-glucosidase inhibitors, such as miglitol or asarabose; peptides or peptide analogs, such as glucagon-like peptide I, gastric inhibitory peptide, exenatide, exendin-4, liraglutide or taspoglatide; DPP-IV inhibitors, such as vilda
- compounds of formula 5 can be synthesized starting from commercially available compounds such as of formula 1. These carbonyl compounds upon Wittig type condensation with methylenediphosphonate ester in presence of a base result in the homologoted unsaturated phosphonate adducts (Xu et al, J Org. Chem., 1996, 61, 7697-7701). The resulting olefins undergo facile hydrogenation to give trans-1,4- or 1,3-substituted (depending on n variable of the starting materials of formula 1) compounds of formula 2. The conditions of such hydrogenations may be similar to the earlier reported protocols as in WO04047755.
- Preparation of compounds of formula 3 from 2 may be attained by selective preparation of monophosphonochloridate followed by reaction with aryl or heteroaryl or alkyl or cycloalkyl magnesium halides as previously reported (Morise et al, J Chem. Soc. Perkin Trans. 1, 1996, 2179-2185).
- H-phosphinates formed from compounds of formula 2 may be coupled to aryl or heteroaryl halide or triflate under palladium catalyzed reaction conditions to introduce —X2-W group as in formula 3 (Bennett et al, J Chem. Soc. Perkin Trans. L 1995, 1145-1151).
- Synthesis of compounds of formula 4 from 3 can be attained as described earlier in WO04047755.
- Deprotection of phosphorus ester of 4 can be achieved by a variety of methods depending on the choice of R′ group.
- Alkyl esters undergo deprotection under bromotrimethyl silane (TMSBr) hydrolysis conditions. Hexamethyl disilazane is used as an additive with TMSBr where the substrate is acid-sensitive. Acid mediated deprotection conditions are used fort-butyl esters.
- TMSBr bromotrimethyl silane
- Acid mediated deprotection conditions are used fort-butyl esters.
- phenyl substituted esters deprotection may be achieved by base hydrolysis.
- benzyl or allyl esters undergo deprotection in neutral conditions such as hydrogenation in the presence of a catalyst and reaction by palladium catalysis, respectively.
- Z group substitution may be introduced at a later stage of the synthesis as shown in scheme 3.
- Such a synthetic strategy may be applied to prepare compounds of formula 11 from 10 where Q is substituted with Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 8 , or Q 9 .
- Compounds of formula 10 can be attained following earlier described procedures in WO04047755, WO08067257, WO08134690, WO08134693, WO06064189, WO06134317, WO07071966, WO07138304, WO07138311, WO07141502, WO07141517, WO07141538, WO07141545, WO07144571, and WO08129319.
- Z group substitution is accomplished by coupling of compounds of formula 7 with 10.
- Such coupling reactions where X 1 of 10 is O or S and leaving group (LG) of 7 is Cl or a substituted or non-substituted phenyl group can be achieved by magnesium alkoxides mediated reactions (WO07022073).
- Compounds of formula 7 may be synthesized by a nucleophilic displacement reaction of 8.
- compounds of Formula 7 can be prepared by applying other methods known in the art. For example, Pd-catalyzed reactions of aryl, heteroaryl or enol triflate (Kalek et al, Org. Lett., 2008, 10, 4637-4640, Bonniller et al, J Org. Chem.
- Compounds that have heterocyclic substitution as in 15 may be obtained from 13 via coupling of precursors of formula 12. Such sequence to 15 may be a linear synthesis as in scheme 1 or convergent sequence as in scheme 3. Synthesis of compounds of formula 12 can be achieved from commercially available halomethylene phosphonate diesters via the transformations that were described earlier in scheme 1, in the conversion of compounds of formula 2 to 3. Base mediated coupling of 12 and 13 to 14 and conversion to 15 may be achieved as described in WO04047755.
- Compounds of formula 17 can be synthesized from 16 where X′′′ is —OH or —NH2 as described in WO09016462.
- Compounds of 16 where X′′′ is —OH may be attained starting from a commercially available hydroxyl substituted 1 following the chemistry described in scheme 1.
- Compounds where X′′′ in 16 is —NH2 are obtained by direct nitration and reduction sequence (WO07141502) from 2, or via 16 where X′′′ is substituted with —OH, by Pd mediated amination of corresponding triflate (WO07141517).
- amine precursor 16 may also be applied in the preparation of compounds of formula 19 with diverse G3 substitution.
- Such amines of 16 or 19 can be utilized in the synthesis of compounds of formulae of 20 to 22.
- Synthetic procedures described in WO05044250, WO06064189, WO06134317, WO07071966, WO07138304, WO07138311, WO07141502, WO07141517, WO07141538, WO07141545, WO07144571, WO08129319 may be utilized for the preparation of compounds of formulae of 20 to 22.
- Compounds of formula 25 can be attained from 16 where X′′′ is —NH 2 , via displacement reaction of a commercially available substituted pyrimidine, pyridine or a phenyl substituted precursor (23). Reduction of the resulting displacement product followed by cyclization with a desired R 8 substituted carboxylic acid or aldehyde result in the compounds of formula 25.
- compounds of 25 can be prepared via a copper mediated N-arylation reaction of 26 and an appropriately functionalized heterocycle as 27 (Jacobsen et al, J. Org. Chem. 2006, 71, 9183-9190).
- Compounds of formulae 31 and 32 can be made from 29 where X′′ is a group selected from Br, I or triflate, utilizing the earlier described procedures (WO07137103, WO07137107, WO06113919).
- Preparation of 29 from 28 or 30 from corresponding unsaturated esters may be obtained by Michael-type additions (Green, Tetrahedron Lett., 1989, 30, 4807-4810).
- Intermediates of formula 30 may be transformed to 29 by Friedel-Crafts acylation reaction (Zhao et al, J Med Chem., 2008, 51, 380-383).
- Preparation of compounds of 34 from intermediate 33 may be attained by utilizing the procedures described before (WO07137103, WO07137107, WO06044775, WO07016538, WO08099221, and WO09011285).
- Substituted amino phosphonic acid esters can be made with the procedures that are well-known in the literature (Chandrasekhar et al, Synlett, 2003, 4, 505-506).
- Monoester 33 can be prepared from corresponding diesters via the reactions described earlier, from 2 to 3.
- Such compounds can also be made in enatiomerically pure form when R 10 and R 11 are not equivalent (Ordonez et al, Tetrahedron, 2009, 65, 17-49).
- the inhibition of DGAT-1 activity can be assessed in intestinal microsome preparations by monitoring the incorporation of radiolabeled fatty acyl-CoA into DAG.
- microsomal preparations containing 60 ug of protein are incubated in assay buffer [20 uM 1,2-didecanloyl glycerol, 5 uM 14 C decanoyl-CoA, 5 mM MgCl 2 , 0.4% BSA, 0.1% dimethyl sulfoxide (DMSO), 50 mM HEPES-pH 7.5] in the presence of varying concentrations of inhibitors that are dispensed from 100% DMSO stock solutions.
- Final assay volumes are 200 uL. Reactions are carried out for 45 minutes in 96-well polystyrene microtiter plates at ambient temperature.
- assay mixtures are applied to a 96-well filter plate (Catalog # MSHVN4510, Millipore Inc.; Billerica, Mass.) under vacuum.
- the filter plate is pre-equilibrated with 100 uL of 70% ethanol followed by 200 uL of assay buffer. Filters are dried, removed and placed in scintillation vials with 4 mL of scintillation cocktail (Catalog #6013329; PerkinElmer Inc.; Waltham, Mass.).
- De novo 14 C-TAG formed in the assay and trapped on the filters is quantified with use of a liquid scintillation counter (Model # LS6500 Beckman Coulter, Inc.; Fullerton, Calif.).
- the IC 50 is defined as the concentration of compound that results in a 50% reduction in TAG synthesis.
- the following screen can be used to evaluate the effects of DGAT-1 inhibitors on the export of dietary TAGs from the intestine to the circulation in rodents (male Sprague Dawley rats or C57BL/6 mice).
- DGAT-1 inhibitors that have low oral bioavailability and show low systemic exposure (i.e. low circulating levels in plasma).
- Results A summary of the key plasma pharmacokinetic parameters of the DGA T-1 inhibitors evaluated is shown in the table below. Compounds of the invention that were tested have low oral bioavailability, ⁇ 10%, and low systemic exposure as indicated by a Cmax ⁇ 0.01 ug/mL. In contrast, known DGAT inhibitors X, Y, and Z were found to have high oral bioavailability and high plasma exposure.
- the following assay can be used to evaluate the anorectic efficacy of DGAT-1 inhibitors rodents (male Sprague Dawley rats or C57BL/6 mice).
- Animals (rats housed I/cage, or mice housed 2/cage) are fasted overnight. The next morning, animals are dosed (PO) with vehicle (1% Tween-80) or test compound (doses ranging from 0.1 to 30 mg/kg). Food is then presented immediately following vehicle or compound administration. Food is weighed manually at 1-3 hour intervals to determine any inhibitory effects on food intake.
- Results Compounds of the invention reduced food intake significantly following oral administration at doses ranging from 0.1 to 30 mg/kg.
- gut hormone e.g., PYY, GLP1, CCK, etc
- Animals Male Sprague Dawley rats or C57BL/6 mice in a fed or fasted state are orally gavaged with a nutrient load (oil, carbohydrate, and/or protein) immediately following administration of vehicle or test compound (doses ranging from 0.01-30 mg/kg). Baseline and temporal bleeds are taken to determine serum concentrations of gut hormones of interest using commercially available ELISA/RIA kits as per the manufacturer's instructions.
- Results Administration of compounds of the invention to rodents at doses ranging from 0.1 to 30 mg/kg results in an increase in one or more gut hormones in plasma.
- DGAT-1 inhibitors The effects of DGAT-1 inhibitors on body weight and adiposity can be assessed in standard animal models of obesity such as the high-fat fed mouse or rat.
- mice (diet-induced obese male, C57BL/6) that have been fed a high fat diet for >12 weeks are sham-dosed bid with water until acclimated to dosing (as determined by stable or steadily increasing body weights). Thereafter, vehicle (1% Tween-80) or test compound (doses ranging from 0.3-30 mg/kg) are dosed (PO, bid) daily for up to 28 days. Food intake and body weights are monitored daily to determine anorectic and weight loss efficacy. At the end of the study, lean and fat mass can be assessed by NMR.
- Results Compounds of the invention significantly reduce body weight and adiposity after daily administration at doses ranging from 0.1 to 30 mg/kg for several days to several weeks.
- the insulin tolerance test was developed to evaluate insulin sensitivity in humans and in animal models (Monzillo et al, Nutrition Reviews, 2003, 61(12):397-412; Bonora et al, J Clin Endocrinol Metab. 1989, 68:374-378; Bergman, Endocrine Reviews, 1985, 6:45-86).
- Diet-induced obese (DIO) mouse or rat models can become insulin resistant with prolonged high fat feeding and have been used to test for improved insulin sensitivity with insulin sensitizing drugs such as glitazones (Guerre-Millo M et al, JBC 2000 275: 16638-42; Schupp M et al; Diabetes, 2005 54: 3442-52; Arulmozhi D K, 2008, 60(9): 1167-73) and in genetically manipulated mice (Fujii N. et al, Diabetes, 2008, 57:2958-66; Funato H et al, Cell Metabolism, 2009, 9(1):64-76).
- insulin sensitizing drugs such as glitazones (Guerre-Millo M et al, JBC 2000 275: 16638-42; Schupp M et al; Diabetes, 2005 54: 3442-52; Arulmozhi D K, 2008, 60(9): 1167-73) and in genetically manipulated mice (
- DIO mice or rats that were subchronically or acutely treated with vehicle or test compound doses ranging from 0.1-30 mg/kg
- doses ranging from 0.1-30 mg/kg are fasted for up to 14 hours and are injected (i.p., 1 U/kg) with Humalog (a fast-acting insulin analog).
- Humalog a fast-acting insulin analog
- the temporal profile of blood glucose levels is monitored using One-Touch glucometers for up to 3 hours post-injection.
- Results Compounds of the invention improve insulin sensitivity after one or multiple weeks of dosing when administered at doses ranging from 0.1 to 30 mg/kg/day to DIO mice or rats. This is evident from the lower glucose levels following insulin administration in the treated versus the control animals.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
-
- Central obesity (excessive fat tissue in and around the abdomen)
- Atherogenic dyslipidemia (blood fat disorders—mainly high triglycerides and low HDL cholesterol—that foster plaque buildups in artery walls)
- Raised blood pressure (130/85 mmHg or higher)
- Insulin resistance or glucose intolerance (the body can't properly use insulin or blood sugar)
- Prothrombotic state (e.g., high fibrinogen or plasminogen activator inhibitor [−1] in the blood)
- Proinflammatory state (e.g., elevated high-sensitivity C-reactive protein in the blood)
-
- Central obesity as measured by waist circumference:
- Men: Greater than 40 inches
- Women: Greater than 35 inches
- Fasting blood triglycerides greater than or equal to 150 mg/dL
- Blood HDL cholesterol:
- Men: Less than 40 mg/dL
- Women: Less than 50 mg/dL
- Blood pressure greater than or equal to 130/85 mmHg
- Fasting glucose greater than or equal to 110 mg/dL
- Central obesity as measured by waist circumference:
Q-G1-G2-G3-G4-Z Formula(I)
wherein Q is Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, or Q9, as defined herein and for each of Q1, Q2, Q3, Q4, Q5, Q6, Q7, Q8, or Q9, common substituents found in the structures are defined as follows: R1 is selected from the group consisting of H, (C1-C8)alkyl, halo(C1-C4)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, C(O)Ra, ORa and NRaRb; optionally, when X is C(R4), Ra or Rb may be combined with R4 or R4 may be combined with R1 to form a 5-, 6- or 7-membered fused ring; Ra and Rb are independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, fluoro(C1-C8)alkyl, (C3-C8)cycloalkyl, aryl, heteroaryl and aryl(C1-C4)alkyl; R2 and R3 are independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, C(O)Ra, CO2Ra, C(O)NRaRb, (C1-C4)alkylene-ORa and (C1-C4)perfluoroalkyl; or R2 and R3 may be combined to form a 3-, 4-, 5- or 6-membered spiro ring; optionally, having from 0 to 3 heteroatoms selected from the group consisting of N, O and S; each R4 is independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, fluoro(C1-C8)alkyl, aryl, aryl(C1-C4)alkyl, C(O)Ra, CO2Ra and C(O)NRaRb; R6 is an optionally substituted aryl or optionally substituted heteroaryl group, wherein the optional substituents are one or more groups selected from H, (C1-C4)alkyl, halo, halo(C1-C4)alkyl, cyano, (C1-C4)alkoxy, (C1-C4)haloalkoxy, —C(O)xRa, —ORa, —S(O)xRa, —NRaRb, —C(O)NRaRb, —NRaC(O)Rb, —NRaCO NRaRb, —S(O)2NRaRb or —NRaS(O)2NRaRb where x is an integer of 1 or 2; T is N, CH or CMe; R8 is independently selected from halo, (C1-C6)alkyl, (C2-C6)alkenyl, aryl, heteroaryl, (C3-C8)cycloalkyl, cyano, (C1-C6)haloalkyl, (C1-C6)haloalkoxy, —ORa, —O—C(O)(Ra), —S(Ra), —S(O)(Rb), —S(O)2(Rb), —C(O)(Ra), —C(O)(ORa), —N(Ra)2, —N(Ra)—C(O)(Ra), —C(O)N(Ra)2, —S(O)2N(Ra)2, —(CRaRb)tORa, —(CRaRb)t—O—C(O)(Ra), —(CRaRb)tS(Ra), —(CRaRb)tS(O)(Rb), —(CRaRb)tS(O)2(Rb), —(CRaRa)tC(O)(Ra), —(CRaRb)tC(O)(ORa), —(CRaRb)rN(RaRb)(CRaRb)tN(Ra)—C(O)(Ra), —(CRaRb)tC(O)N(Ra)2, —(CRaRa)tS(O)2N(Ra)2 or —(CRaRb)tRa and wherein t is an integer of 1, 2, 3, or 4; Q1 is
wherein J is selected from —NRaRb or —ORa; X is selected from the group consisting of C(R4) and N; optionally, when X is C(R4), Ra or Rb may be combined with R4 or R4 may be combined with R1 to form a 5-, 6- or 7-membered fused ring; E is selected from the group consisting of 0 and S; Q2 is
R5 is H or (C1-C4)alkyl; X is N or C(R4) and when X is C(R4), R4 may be combined with R1 to form a 5-, 6- or 7-membered fused ring; R2 and R3 are as defined above or may be combined with R5 to form a 3-, 4-, 5- or 6-membered spiro ring; optionally, having from 0 to 3 heteroatoms selected from the group consisting of N, O and S; Q3 is
Q6 is R7(V)nC(O)(NH)m—; R7 is (C1-C8)alkyl, aryl, heteroaryl or (C3-C8)cycloalkyl; wherein each of the aryl, heteroaryl and cycloalkyl is independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, —CN, halogen, ethylenedioxy, methylenedioxy, haloalkyl, —ORa, —O—C(O)(Ra), —S(Ra), —S(O)(Rb), —S(O)2(Rb), —C(O)(Ra), —C(O)(ORa), —N(Ra)2, —N(Ra)—C(O)(Ra), —C(O)N(Ra)z, —S(O)2N(Ra)2, —(CRaRb)tORa, —(CRaRb), —O—C(O)(Ra), —(CRaRb)tS(Ra), —(CRaRb)tS(O)(Rb), —(CRaRb)tS(O)2(Rb), —(CRaRa)tC(O)(Ra), —(CRaRb)tC(O)(ORa), —(CRaRb)rN(RaRb) (CRaRb)tN(Ra)—C(O)(Ra), —(CRaRb)tC(O)N(Ra)2, —(CRaRa)tS(O)2N(Ra)2 and —(CRaRb)tRa, V is —NH—, —O—, —(CRaRb)t—; where t is an integer of 1, 2, 3, or 4; m is 0 or 1; n is 0 or 1; Q7 is
wherein D is O, NW, or S; and A is a fused ring selected from an aromatic 6-membered ring containing 0 or 2 N atoms; the number of R8 substituents on A ring may be 0, 1 or 2 and when two of said R8 substituents are: a) found on A ring; b) (C1-C6)alkyl and c) attached to adjacent carbon atoms of the Ring A, they may be joined together to form a 5 to 7-membered carbocyclic ring; and RC is H or (C1-C6)alkyl, hydroxyl(C2-C6)alkyl; Q8·is
L is N or C(R8); and the number of R8 substituents on A ring may be 0, 1, 2 or 3 and when two of said R8 substituents are: a) found on A ring; b) (C1-C6)alkyl and c) attached to adjacent carbon atoms of the Ring A, they may be joined together to form a 5- to 7-membered carbocyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N, S; or Q9 is a [5,5], [5,6], [6,5] and [6,6] bicyclic heterocycle containing 1 to 4 N atoms where G1 is connected through one of the ring N atoms; G1 and G3 are independently selected from the group consisting of cyclo(C3-C8)alkylene, heterocyclo(C3-C8)alkylene, arylene and heteroarylene, optionally substituted with one or two groups independently selected from halo, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, cyano, (C1-C6)halo alkyl, (C1-C6)haloalkoxy, (C1-C4)perfluoroalkyl; —N(RaRb), —N(Ra)—C(O)(Ra), —C(O)N(Ra)2, —S(O)2N(Ra)2, —S(O)2(Rb) and —C(O)(Ra).
X1 and X2 are independently selected from null, (C(RaRb))n, O, NRa, S or CO and n is 0 or 1; W is selected from H, (C1-C6)alkyl, aryl, heteroaryl or (C3-C8)cycloalkyl; wherein each of the alkyl, aryl, heteroaryl and cycloalkyl is independently substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of (C1-C6)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, —CN, halogen, ethylenedioxy, methylenedioxy, haloalkyl, —Ora, —O—C(O)(Ra), —S(Ra), —S(O)(Rb), —S(O)2(Rb), —C(O)(Ra), —C(O)(ORa), —N(Ra)2, —N(Ra)—C(O)(Ra), —C(O)N(Ra)2, —S(O)2N(Ra)2, —(CRaRb)tORa, —(CRaRb)t—O—C(O)(Ra), —(CRaRb)tS(Ra), (CRaRb)tS(O)(Rb), —(CRaRb)tS(O)2(Rb), —(CRaRa)tC(O)(Ra), —(CRaRb)tC(O)(ORa), (CRaRb)tN(RaRb)—(CRaRb)tN(Ra)—C(O)(Ra), —(CRaRb)tC(O)N(Ra)2, —(CRaRa)tS(O)2N(Ra)2 and —(CRaRb)tRa, —(CRaRb)tP(O)(OH)2, and —(CRaRb)tP(O)(OH)(Ra), wherein t is an integer of 1, 2, 3, or 4; X1 and X2 may be combined to form a 5-, 6- or 7-membered ring having from 0 to 3 heteroatoms selected from the group consisting of NRa, O and S; or X1 or X2 may be combined with W to form a 5-, 6- or 7-membered fused ring having from 0 to 3 heteroatoms selected from the group consisting of Nra, O and S; Z2 is Z1, H, —OH, CO2Ra or —C(O)N(Ra)2; with a proviso that when X2 is O and Q is Q1, Q2, Q3, Q4, Q5, Q6, Q7 or Q9, then X1 is not (C(RaRb))n and when Q is Q8 then Z is Z2 and Z2 is Z1, H, —OH, CO2Ra or —C(O)N(Ra)2.
TABLE 1 |
ELEMENTAL ANALYSIS AND MASS SPEC DATA OF CERTAIN COMPOUNDS OF THE PRESENT INVENTION |
Elemental Analysis | Mass | ||
Compound | CHN (calcd) CHN (Found) | Spec | |
Number | Structure | Formula | MH+ |
1 | | C: 60.40, H: 6.91, N: 12.81 C: 60.81, H: 7.29, N: 12.42 C22H29N4O3P + 0.5 H2O | 429 |
2 | | C: 64.99, H: 6.08, N: 5.83 C: 64.75, H: 6.03, N: 5.40 C26H21N2O4P + 1.0 H2O | 463 |
3 | | C: 53.82, H: 6.59, N: 11.52 C: 53.55, H: 6.24, N: 11.64 C20H25N4O5P + 1.0 H2O + 0.6 i-PrOH | 433 |
4 | | C: 56.24, H: 6.52, N: 12.49 C: 55.76, H: 6.57, N: 12.13 CHN4O4 + 1.0 H2O | 431 |
5 | | C: 55.31, H: 5.25, N: 11.22 C: 55.11, H: 4.87, N: 11.18 C23H25F2N4O4P + 0.5 H2O | 491 |
6 | | C: 50.18, H: 4.90, N: 12.72 C: 50.13, H: 4.66, N: 12.80 C18H20ClN4O3P + 0.6 H2O + 0.2 CF3CO2H | 407 |
7 | | C: 56.93, H: 6.61, N: 6.64 C: 57.09, H: 6.68, N: 6.81 C24H27N2O5P + 2.5 H2O + 0.4 NH3 | 455 |
8 | | C: 57.73, H: 6.90, N: 11.22 C: 57.78, H: 7.28, N: 10.79 C24H33N4O5P + 0.6 H2O | 489 |
9 | | C: 51.36, H: 6.86, N: 10.89 C: 50.96, H: 6.49, N: 10.60 C22H29N4O5P + 3.0 H2O | 461 |
10 | | C: 53.62, H: 7.13, N: 10.01 C: 53.21, H: 6.54, N: 9.84 C25H33N4O5P + 3.3 H2O | 501 |
11 | | C: 61.82, H: 6.34, N: 10.68 C: 61.35, H: 6.20, N: 10.65 C27H31N4O4P + 1.0 H2O | 507 |
12 | | C: 60.64, H: 6.36, N: 10.10 C: 60.98, H: 6.39, N: 9.62 C28H33N4O5P + 1.0 H2O | 537 |
13 | | C: 56.26, H: 6.82, N: 11.93 C: 56.19, H: 6.69, N: 11.76 C22H29N4O4P + 1.4 H2O | 445 |
14 | | C: 62.27, H: 6.03, N: 11.17 C: 61.88, H: 5.66, N: 11.02 C26H29N4O4P + 0.5 H2O | 493 |
15 | | C: 55.66, H: 6.67, N: 10.74 C: 55.98, H: 7.07, N: 11.06 C29H35N4O3P + 1.6 H2O + 0.8 NH4Br | 519 |
16 | | C: 62.39, H: 7.45, N: 11.19 C: 62.61, H: 7.39, N: 11.40 C26H35N4O3P + 1.0 H2O | 483 |
17 | | C: 58.23, H: 5.93, N: 9.70 C: 58.02, H: 5.61, N: 9.47 C28H31N4O6P + 1.5 H2O | 551 |
18 | | C: 45.09, H: 4.83, N: 7.25 9 C: 44.95, H: 5.17, N: 6.98 C28H29N4O6PNa2 + 4.0 H2O + 1.0 Na2CO3 | 551 |
19 | | C: 57.00, H: 5.54, N: 11.08 C: 56.85, H: 5.57, N: 10.92 C24H27N4O4SP + 0.4 H2O | 499 |
20 | | C: 57.00, H: 5.54, N: 11.08 C: 57.09, H: 5.39, N: 11.13 C24H27N4O4SP + 0.4 H2O | 499 |
21 | | C: 64.92, H: 6.46, N: 11.22 C: 64.78, H: 6.49, N: 11.03 C27H31N4O3P + 0.5 H2O | 491 |
22 | | C: 61.18, H: 7.14, N: 12.41 C: 61.33, H: 7.27, N: 12.26 C23H31N4O3P + 0.5 H2O | 444 |
23 | | C: 62.19, H: 6.96, N: 12.09 C: 62.17, H: 6.87, N: 11.91 C24H31N4O3P + 0.5 H2O | 455 |
24 | | 425 | |
25 | | C: 58.35, H: 6.07, N: 10.89 C: 59.34, H: 6.06, N: 10.86 C25H29N4O3PS + 1 H2O | 497 |
26 | | C: 59.82, H: 5.94, N: 11.16 C: 60.04, H: 6.09, N: 10.94 C25H29N4O3PS + 0.3 H2O | 497 |
27 | | C: 54.05, H: 5.66, N: 12.01 C: 54.36, H: 5.75, N: 11.54 C21H24ClN4O3P + 1.1 H2O | 447 |
28 | | C: 56.13, H: 5.38, N: 10.91 C: 56.39, H: 5.38, N: 10.30 C24H24ClN4O3P + 1.7 H2O | 483 |
29 | | C: 49.88, H: 6.05, N: 12.93 C: 49.67, H: 5.23, N: 12.82 C18H21N4O4P + 2.5 H2O | 389 |
30 | | C: 57.67, H: 5.96, N: 12.93 C: 57.83, H: 5.80, N: 10.48 C26H30N5O5P + 1.0 H2O | 524 |
31 | | C: 59.65, H: 5.78, N: 13.38 C: 59.68, H: 5.81, N: 10.84 C26H30N5O5P | 524 |
32 | | C: 61.92, H: 7.61, N: 11.55 C: 62.11, H: 8.15, N: 11.19 C25H35N4O3P + 0.8 H2O | 471 |
33 | | C: 59.84, H: 7.49, N: 11.63 C: 59.64, H: 7.88, N: 11.31 C24H33N4O3P + 1.4 H2O | 457 |
34 | | C: 60.22, H: 5.90, N: 10.40 C: 60.55, H: 6.30, N: 10.08 C27H30ClN4O3P + 0.75 H2O | 525 |
35 | | C: 54.30, H: 5.87, N: 17.59 C: 54.59, H: 5.71, N: 17.17 C18H22N5O3P + 0.6 H2O | 388 |
36 | | C: 51.03, H: 4.28, N: 11.44 C: 51.33, H: 4.40, N: 11.67 C24H25ClN5O3P + 1.0 CF3CO2H | 498 |
37 | | C: 48.16, H: 4.88, N: 12.42 C: 48.37, H: 4.96, N: 12.77 C20H26N5O3P + 1.3 CF3CO2H | 416 |
38 | | C: 52.23, H: 4.50, N: 11.45 C: 52.16, H: 4.40, N: 11.57 C24H26N5O3P + 1.3 CF3CO2H | 464 |
39 | | 478 | |
40 | | C. 58.06, H: 5.68 N: 15.05 C: 57.83, H: 5.68 N: 14.97 C18H21N4O3P | 373 |
41 | | 415 | |
42 | | 417 | |
43 | | 423 | |
44 | | 590 | |
45 | | 534 | |
46 | | 348 | |
47 | | 294 | |
48 | | 309 | |
49 | | 328 | |
50 | | 313 | |
51 | | 491 | |
52 | | 390 | |
53 | | 449 | |
Preparation of Compounds
TABLE 2 |
DGAT-1 INHIBITION OF COMPOUNDS |
OF THE PRESENT INVENTION |
Compound Number | hDGAT1 IC50* | |
1 | A | |
2 | B | |
3 | A | |
5 | A | |
6 | C | |
7 | C | |
8 | A | |
9 | A | |
10 | A | |
11 | A | |
12 | B | |
13 | A | |
14 | A | |
17 | A | |
18 | B | |
19 | A | |
20 | A | |
21 | A | |
22 | B | |
23 | A | |
24 | C | |
25 | B | |
26 | B | |
30 | B | |
31 | B | |
32 | B | |
33 | B | |
34 | B | |
*‘A’ represents IC50 value <10 nM ‘B’ represents IC50 value between 10 andlOO nM ‘C’ represents IC50 value between 100 and 1000 nM |
TABLE 3 |
KEY PLASMA PHARMACOKINETIC PARAMETERS |
OF DGAT-1 INHIBITORS1,2 |
Compound | Oral Bioavailiability, % | Cmax, ug/Ml |
X | 75 | 4.81 |
Y | 70 | 3.33 |
Z | 67 | 8.68 |
1 | 5.6 | 0.009 |
2 | 1.1 | 0.005 |
5 | 0.9 | 0.003 |
1LOQ-- 0.001 ug/mL | ||
2Compound X, Compound 2 of Birch et al, J. Med. Chem., 2009 (DOI: 10.1021/jm801507v); Compound Y, compound 1 of Birch et al, J Afed Chem., 2009 (DOI: 10.1021/jm801507v); Compound Z, Example 1 ofW007144571. |
- Chen, H. C., Stone, S. J., Zhou, P., Buhman, K. K., Farese, R. V. Jr. (2002) “Dissociation of obesity and impaired glucose disposal in mice overexpressing acyl coenzyme a:diacylglycerol acyltransferase 1 in white adipose tissue” Diabetes 51(11):3189-95.
- Chen, H. C., Farese, R. V. Jr. (2005) “Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice” Arterioscler Thromb Vase Biol 25(3):482-6.
- Hill, J. O., Melanson, E. L., Wyatt, H. T. (2000) “Dietary fat intake and regulation of energy balance: implications for obesity” J Nutr. 30(2S Suppl):2845-2885.
- Shi, Y., Burn, P. (2004) “Lipid metabolic enzymes: emerging drug targets for the treatment of obesity” Nat Rev Drug Discov 3 (8): 695-710.
- Smith, S. J., Cases, S., Jensen, D. R., Chen, H. C., Sande, E., Tow, B., Sanan, D. A., Raber, J., Eckel, R. H., Farese, R. V. Jr. (2000) “Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat” Nat Genet 25(1):87-90.
- Stone, S. J., Myers, H. M., Watkins, S. M., Brown, B. E., Feingold, K. R., Elias, P. M., Farese, R. V. Jr (2004) “Lipopenia and skin barrier abnormalities in DGAT2-deficient mice” J Biol Chem. 19; 279(12): 11767-76.
- Van Herpen, N. A., Schrauwen-Hinderling, V. B. (2008) “Lipid accumulation in non-adipose tissue and lipotoxicity” Physiol Behav 94(2):231-41.
- Yamazaki, T., Sasaki, E., Kakinuma, C., Yano, T., Miura, S., Ezaki, O. (2005) “Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1” J Biol Chem. 280(22):21506-14.
- Yen, C. L., Monetti, M., Burri, B. J., Farese, R. V. Jr. (2005) “The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters” J Lipid Res 46(7): 15 02-11.
- Yen, C. L., Stone, S. J., Koliwad, S., Harris, C., Farese, R. V. Jr. (2008) “Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis” J Lipid Res 49(11):2283-301.
- Zhao, G., Souers, A. J., Voorbach, M., Falls, H. D., Droz, B., Brodjian, S., Lau, Y. Y., Iyengar, R. R., Gao, J., Judd, A S., Wagaw, S. H., Ravn, M. M., Engstrom, K. M., Lynch, J. K., Mulhern, M. M., Freeman, J., Dayton, B. D., Wang, X., Grihalde, N., Fry, D., Beno, D. W., Marsh, K. C., Su, Z., Diaz, G. J., Collins, C. A., Sham, H., Reilly, R. M., Brune, M. E., Kym, P. R. (2008) “Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor” J Med Chem 51(3):380-3
Claims (11)
Q-G1-G2-G3-G4-Z Formula (I)
Q-G1-G2-G3-G4-Z Formula (I)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/025,199 US10709718B2 (en) | 2009-03-20 | 2018-07-02 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16217009P | 2009-03-20 | 2009-03-20 | |
PCT/US2010/027889 WO2010108051A2 (en) | 2009-03-20 | 2010-03-19 | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
US201113256952A | 2011-09-16 | 2011-09-16 | |
US13/458,452 US8962618B2 (en) | 2009-03-20 | 2012-04-27 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US14/628,373 US9340566B2 (en) | 2009-03-20 | 2015-02-23 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US15/151,740 US10034891B2 (en) | 2009-03-20 | 2016-05-11 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US16/025,199 US10709718B2 (en) | 2009-03-20 | 2018-07-02 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/151,740 Continuation US10034891B2 (en) | 2009-03-20 | 2016-05-11 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180303856A1 US20180303856A1 (en) | 2018-10-25 |
US10709718B2 true US10709718B2 (en) | 2020-07-14 |
Family
ID=42227790
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/458,452 Expired - Fee Related US8962618B2 (en) | 2009-03-20 | 2012-04-27 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US14/628,373 Active US9340566B2 (en) | 2009-03-20 | 2015-02-23 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US15/151,740 Active US10034891B2 (en) | 2009-03-20 | 2016-05-11 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US16/025,199 Active US10709718B2 (en) | 2009-03-20 | 2018-07-02 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/458,452 Expired - Fee Related US8962618B2 (en) | 2009-03-20 | 2012-04-27 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US14/628,373 Active US9340566B2 (en) | 2009-03-20 | 2015-02-23 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US15/151,740 Active US10034891B2 (en) | 2009-03-20 | 2016-05-11 | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
Country Status (4)
Country | Link |
---|---|
US (4) | US8962618B2 (en) |
EP (3) | EP2805951B1 (en) |
DK (1) | DK3366686T3 (en) |
WO (1) | WO2010108051A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2805951B1 (en) * | 2009-03-20 | 2018-03-14 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof |
AU2012340200B2 (en) | 2011-11-17 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-Terminal Kinase (JNK) |
CN104418866B (en) | 2013-08-23 | 2018-10-16 | 青岛黄海制药有限责任公司 | Dgat1 inhibitor and its preparation method and application |
CN112272668B (en) * | 2018-06-27 | 2023-05-09 | 伊万·希利奥·奥利弗 | Novel substituted N9-adenine derivatives, pharmaceutical compositions containing the same and uses thereof |
CN116687850A (en) | 2022-02-24 | 2023-09-05 | 甘莱制药有限公司 | Pharmaceutical composition containing cyclic phosphonate compound, preparation method and application thereof |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110903A (en) | 1997-03-07 | 2000-08-29 | Sankyo Company Ltd. | Benzimidazole inhibitors of fructose 1,6-bisphosphatase |
US6489476B1 (en) | 1998-09-09 | 2002-12-03 | Metabasis Therapeutics, Inc. | Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase |
WO2004047755A2 (en) | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
WO2005044250A1 (en) | 2003-10-29 | 2005-05-19 | Astrazeneca Ab | Use of sulfonamide compounds for the treatment of diabetes and/or obesity |
US6919322B2 (en) | 2000-03-08 | 2005-07-19 | Metabasis Therapeutics, Inc. | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors |
WO2005072740A2 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
US6965033B2 (en) | 1999-12-22 | 2005-11-15 | Metabasis Therapeutics, Inc. | Bisamidate phosphonate prodrugs |
US6967193B1 (en) | 1997-03-07 | 2005-11-22 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose-1,6-bisphosphatase |
WO2006023654A2 (en) | 2004-08-16 | 2006-03-02 | The Trustees Of Columbia University In The City Of New York | Awat-related methods and articles |
WO2006044775A2 (en) | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
WO2006064189A1 (en) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2006113919A2 (en) | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Aryl alkyl acid derivatives for and use thereof |
WO2006134317A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2007016538A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
WO2007022073A2 (en) | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
WO2007137107A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007137103A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007138311A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
WO2007138304A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
WO2007141538A1 (en) | 2006-06-10 | 2007-12-13 | Astrazeneca Ab | Oxazole derivatives and their use in the treatment of diabetes and obesity |
WO2007141517A1 (en) | 2006-06-08 | 2007-12-13 | Astrazeneca Ab | Benzimidazoles and their use for the treatemnt of diabetes |
WO2007141545A1 (en) | 2006-06-10 | 2007-12-13 | Astrazeneca Ab | Compounds for the inhibition of dgat1 activity |
WO2007141502A1 (en) | 2006-06-06 | 2007-12-13 | Astrazeneca Ab | Chemical compounds |
WO2007144571A1 (en) | 2006-06-12 | 2007-12-21 | Astrazeneca Ab | Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid |
WO2008067257A2 (en) | 2006-11-29 | 2008-06-05 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2008073865A2 (en) | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
WO2008099221A1 (en) | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
WO2008129319A1 (en) | 2007-04-20 | 2008-10-30 | Astrazeneca Ab | Salts of oxadiazole derivatives as dgat inhibitors |
WO2008134690A1 (en) | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2008134693A1 (en) | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2009011285A1 (en) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | Heteroarylbenzene compounds |
WO2009016462A2 (en) | 2007-08-02 | 2009-02-05 | Pfizer Products Inc. | Substituted bicyclolactam compounds |
WO2010108051A2 (en) | 2009-03-20 | 2010-09-23 | Ligand Pharmaceuticals | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
KR101804588B1 (en) | 2009-10-13 | 2017-12-04 | 리간드 파마슈티칼스 인코포레이티드 | Hematopoietic growth factor mimetic small molecule compounds and their uses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525356B1 (en) | 1998-12-15 | 2003-02-25 | Nec Corporation | Solid imaging device |
-
2010
- 2010-03-19 EP EP14172611.7A patent/EP2805951B1/en not_active Not-in-force
- 2010-03-19 DK DK18150958.9T patent/DK3366686T3/en active
- 2010-03-19 EP EP10710137.0A patent/EP2408774B1/en not_active Not-in-force
- 2010-03-19 EP EP18150958.9A patent/EP3366686B9/en active Active
- 2010-03-19 WO PCT/US2010/027889 patent/WO2010108051A2/en active Application Filing
-
2012
- 2012-04-27 US US13/458,452 patent/US8962618B2/en not_active Expired - Fee Related
-
2015
- 2015-02-23 US US14/628,373 patent/US9340566B2/en active Active
-
2016
- 2016-05-11 US US15/151,740 patent/US10034891B2/en active Active
-
2018
- 2018-07-02 US US16/025,199 patent/US10709718B2/en active Active
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399782B1 (en) | 1997-03-07 | 2002-06-04 | Metabasis Therapeutics, Inc. | Benzimidazole inhibitors of fructose 1,6-bisphosphatase |
US6110903A (en) | 1997-03-07 | 2000-08-29 | Sankyo Company Ltd. | Benzimidazole inhibitors of fructose 1,6-bisphosphatase |
US6967193B1 (en) | 1997-03-07 | 2005-11-22 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose-1,6-bisphosphatase |
US6489476B1 (en) | 1998-09-09 | 2002-12-03 | Metabasis Therapeutics, Inc. | Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase |
US6965033B2 (en) | 1999-12-22 | 2005-11-15 | Metabasis Therapeutics, Inc. | Bisamidate phosphonate prodrugs |
US6919322B2 (en) | 2000-03-08 | 2005-07-19 | Metabasis Therapeutics, Inc. | Phenyl Phosphonate Fructose-1,6-Bisphosphatase Inhibitors |
WO2004047755A2 (en) | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
WO2005044250A1 (en) | 2003-10-29 | 2005-05-19 | Astrazeneca Ab | Use of sulfonamide compounds for the treatment of diabetes and/or obesity |
WO2005072740A2 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
WO2006023654A2 (en) | 2004-08-16 | 2006-03-02 | The Trustees Of Columbia University In The City Of New York | Awat-related methods and articles |
WO2006044775A2 (en) | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
WO2006064189A1 (en) | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2006113919A2 (en) | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Aryl alkyl acid derivatives for and use thereof |
WO2006134317A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
WO2007016538A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity |
WO2007022073A2 (en) | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
WO2007071966A1 (en) | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors |
WO2007137107A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007137103A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007138304A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
WO2007138311A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
WO2007141502A1 (en) | 2006-06-06 | 2007-12-13 | Astrazeneca Ab | Chemical compounds |
WO2007141517A1 (en) | 2006-06-08 | 2007-12-13 | Astrazeneca Ab | Benzimidazoles and their use for the treatemnt of diabetes |
WO2007141538A1 (en) | 2006-06-10 | 2007-12-13 | Astrazeneca Ab | Oxazole derivatives and their use in the treatment of diabetes and obesity |
WO2007141545A1 (en) | 2006-06-10 | 2007-12-13 | Astrazeneca Ab | Compounds for the inhibition of dgat1 activity |
WO2007144571A1 (en) | 2006-06-12 | 2007-12-21 | Astrazeneca Ab | Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid |
WO2008067257A2 (en) | 2006-11-29 | 2008-06-05 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2008073865A2 (en) | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia |
WO2008099221A1 (en) | 2007-02-15 | 2008-08-21 | Prosidion Limited | Amide and urea derivatives for the treatment of metabolic diseases |
WO2008129319A1 (en) | 2007-04-20 | 2008-10-30 | Astrazeneca Ab | Salts of oxadiazole derivatives as dgat inhibitors |
WO2008134690A1 (en) | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2008134693A1 (en) | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2009011285A1 (en) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | Heteroarylbenzene compounds |
WO2009016462A2 (en) | 2007-08-02 | 2009-02-05 | Pfizer Products Inc. | Substituted bicyclolactam compounds |
WO2010108051A2 (en) | 2009-03-20 | 2010-09-23 | Ligand Pharmaceuticals | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
EP2408774A2 (en) | 2009-03-20 | 2012-01-25 | Ligand Pharmaceuticals | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
EP2805951A2 (en) | 2009-03-20 | 2014-11-26 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (DGAT-1) and uses thereof |
US8962618B2 (en) | 2009-03-20 | 2015-02-24 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US9340566B2 (en) | 2009-03-20 | 2016-05-17 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
US10034891B2 (en) | 2009-03-20 | 2018-07-31 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof |
EP3366686A2 (en) | 2009-03-20 | 2018-08-29 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof |
KR101804588B1 (en) | 2009-10-13 | 2017-12-04 | 리간드 파마슈티칼스 인코포레이티드 | Hematopoietic growth factor mimetic small molecule compounds and their uses |
Non-Patent Citations (31)
Title |
---|
Ando, K. "Convenient Preparations of (Diphenylphosphono)acetic Acid Esters and the Comparison of the Z-Selectivities of Their Horner-Wadsworth-Emmons Reaction with Aldehydes Depending on the Ester Moiety" J. Org. Chem., 1999, pp. 8406-8408, vol. 64. |
Arulmozhi, D. K. et al. "Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes" Journal of Pharmacy and Pharmacology, 2008, pp. 1167-1173, vol. 60. |
Bennett, S. N. L. et al. "New syntheses of arylphosphinic acids from the reaction of ethyl diethoxymethylphosphinate with aryl bromides and phenols" J. Chem. Soc. Perkin Trans, 1995, pp. 1145-1151, vol. 1. |
Bergman, R. N. et al. "Assessment of Insulin Sensitivity in Vivo" Endocrine Reviews, 1985, pp. 45-86, vol. 6, No. 1. |
Birch, A. M. et al. "Discovery of a Potent, Selective, and Orally Efficacious Pyrimidinooxazinyl Bicyclooctaneacetic Acid Diacylglycerol Acyltransferase-1 Inhibitor" Journal of Medicinal Chemistry, 2009, pp. 1558-1568, vol. 52, No. 6. |
Bonnaventure, I. et al. "Probing the Importance of the Hemilabile Site of Bis(phosphine) Monoxide Ligands in the Copper-Catalyzed Addition of Diethylzinc to N-Phosphinoylimines: Discovery of New Effective Chiral Ligands" J. Org. Chem., 2008, pp. 6330-6340, vol. 73. |
Bonora, E. et al. "Estimates of in Vivo Insulin Action in Man: Comparison of Insulin Tolerance Tests with Euglycemic and Hyperglycemic Glucose Clamp Studies" Journal of Clinical Endocrinology and Metabolism, 1989, p. 374-378, vol. 68, No. 2. |
Boyd, E. A. et al. "Facile Synthesis of Phosphorus-containing Heterocycles" Tetrahedron Letters, 1996, pp. 5425-5426, vol. 37, No. 30. |
Chandrasekhar, S. et al. "Solvent and Catalyst Free Three-component Coupling of Carbonyl Compounds, Amines and Triethylphosphite; a new Synthesis of alpha-Amino-phosphonates" Synlett, 2003, pp. 505-506, vol. 4. |
CHEMICAL ABSTRACTS, 2 March 2006, Columbus, Ohio, US; STURLEY STEPHEN L, TURKISH AARON, BILLHEIMER JEFFREY, CROMLEY DEBRA: "awat-related compounds. for metabolic or sebaceous gland disorders" XP002733266 |
European Extended Partial Search Report, re EP Application No. 18150958.9, dated Jun. 21, 2018. |
European Extended Search Report, re EP Application No. 14172611.7, dated Mar. 30, 2015. |
European Partial Search Report, re EP Application No. 14172611.7, dated Dec. 17, 2014. |
Freeman, S. et al. "Prodrug Design for Phosphates and Phosphonates" Progress in Medicinal Chemistry, 1997, pp. 111-147, vol. 34. |
Fujii, N. et al. "Ablation of AMP-Activated Protein Kinase alpha2 Activity Exacerbates Insulin Resistance Inducted by High-Fat Feeding of Mice" Diabetes, Nov. 2008, pp. 2958-2966, vol. 57. |
Funato, H. et al. "Enhanced Orexin Receptor-2 Signaling Prevents Diet-Induced Obesity and Improves Leptin Sensitivity" Cell Metabolism, Jan. 7, 2009, pp. 64-76, vol. 9. |
Green, K. "Trimethylaluminium Promoted Conjugate Additions of Dimethylphosphite to alpha,beta-Unsaturated Esters and Ketones" Tetrahedron Letters, 1989, pp. 4807-4810, vol. 30, No. 36. |
Guerre-Millo, M. et al. "Peroxisome Proliferator-activated Receptor alpha Activators Improve Insulin Sensitivity and Reduce Adiposity" The Journal of Biological Chemistry, Jun. 2, 2000, pp. 16638-16642, vol. 275, No. 22. |
He, G.-X. et al. "Chapter 3.6. Prodrugs of Phosphonates, Phosphinates, and Phosphates" Prodrugs Challenges and Rewards Part 1 (Book Series: Biotechnology: Pharmaceutical Aspects), Jan. 1, 2007, pp. 923-964. |
Hubbard, C. E. et al. "A highly efficient route to enantiomerically pure L-N-BZ-PMP (t-Bu)2-OH and incorporation into a peptide-based protein tyrosine phosphatase inhibitor" Bioorganic & Medicinal Chemistry Letters, 2008, pp. 679-681, vol. 18. |
International Preliminary Report on Patentability, re PCT/US2010/027889, dated Sep. 20, 2011. |
International Search Report, re PCT/US2010/027889, dated Sep. 21, 2010. |
International Written Opinion, re PCT/US2010/027889, dated Sep. 21, 2010. |
Jacobsen, M. F. et al. "Efficient N-Arylation and N-Alkenylation of the Five DNA/RNA Nucleobases" J. Org. Chem., 2006, pp. 9183-9190, vol. 71. |
Kalek, M. et al. "Microwave-Assisted Palladium-Catalyzed Cross-Coupling of Aryl and Vinyl Halides with H-Phosphonate Diesters" Organic Letters, 2008, pp. 4637-4640, vol. 10, No. 20. |
Monzillo, L. U. et al. "Evaluation of Insulin Sensitivity in Clinical Practice and in Research Settings" Nutrition Reviews, Dec. 2003, pp. 397-412, vol. 61, No. 12. |
Morise, X. et al. "New syntheses of 1-chloroalkylyphosphinates" J. Chem. Soc., 1996, pp. 2179-2185, vol. 1. |
Ordonez, M. et al. "An overview of stereoselective synthesis of alpha-aminophosphonic acids and derivatives" Tetrahedron, 2009, pp. 17-49, vol. 65. |
Perumal, S. K. et al. "Synthesis and Evaluation of Ketophosph(on)ates as beta-Lactamase Inhibitors" J. Org. Chem., 2000, pp. 4778-4785, vol. 71. |
STN CA Caesar Accession No. 1086, 2006, pp. 1-2, XP-002733266. |
Xu, Y. et al. "Preparation of New Wittig Reagents and Their Application to the Synthesis of alpha,beta-Unsaturated Phosphonates" J. Org. Chem., 1996, pp. 7697-7701, vol. 61. |
Also Published As
Publication number | Publication date |
---|---|
US8962618B2 (en) | 2015-02-24 |
DK3366686T3 (en) | 2020-11-23 |
WO2010108051A2 (en) | 2010-09-23 |
US20180303856A1 (en) | 2018-10-25 |
US9340566B2 (en) | 2016-05-17 |
EP2408774A2 (en) | 2012-01-25 |
EP3366686B1 (en) | 2020-09-09 |
EP3366686A2 (en) | 2018-08-29 |
EP3366686A3 (en) | 2018-10-24 |
US20120270842A1 (en) | 2012-10-25 |
US20150166590A1 (en) | 2015-06-18 |
US20160263132A1 (en) | 2016-09-15 |
EP2805951B1 (en) | 2018-03-14 |
EP2408774B1 (en) | 2014-11-26 |
EP2805951A2 (en) | 2014-11-26 |
WO2010108051A3 (en) | 2010-11-11 |
US10034891B2 (en) | 2018-07-31 |
EP3366686B9 (en) | 2021-08-04 |
EP2805951A3 (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10709718B2 (en) | Inhibitors of diacylglycerol O-acyltransferase 1 (DGAT-1) and uses thereof | |
JP6817190B2 (en) | Methods and compositions for the treatment of metabolic disorders | |
US8410173B2 (en) | Inhibition of JAK2 as a treatment of pulmonary arterial hypertension | |
EP1640010A1 (en) | Agent inducing increase in bone mass | |
US20110183958A1 (en) | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | |
JP2020105206A (en) | Pyrrolopyrimidine compound | |
US20150175610A1 (en) | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | |
US20170275249A1 (en) | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase | |
US20160128985A1 (en) | Methods and Compositions for the Treatment of Body Weight Related Disorders | |
EP1415667B1 (en) | Pancreatic juice secretion regulators comprising lpa receptor controller | |
TW202045496A (en) | Kinase inhibitors | |
US20070167411A1 (en) | Compositions for treating angina | |
RU2763525C2 (en) | Combination therapy for treatment of pulmonary hypertension | |
US9975879B2 (en) | Beta lactams as modulators of glutamate uptake and methods for use thereof | |
US20220218715A1 (en) | Novel use of pyrrolo-pyridine derivative compound for prevention and/or treatment of cancer | |
JPH09183725A (en) | Cancer treating agent | |
WO2021153570A1 (en) | Proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor and pharmaceutical use therefor | |
US20080311099A1 (en) | Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina | |
JP2022504693A (en) | Phosphodiesterase inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: METABASIS THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REDDY, K. RAJA;STEBBINS, JEFF;BOYER, SERGE H.;AND OTHERS;SIGNING DATES FROM 20120524 TO 20120705;REEL/FRAME:046255/0241 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: CITIBANK, N.A., AS ADMINISTRATIVE AGENT, TEXAS Free format text: SECURITY INTEREST;ASSIGNORS:CYDEX PHARMACEUTICALS, INC.;LIGAND PHARMACEUTICALS INCORPORATED;METABASIS THERAPEUTICS, INC.;AND OTHERS;REEL/FRAME:065271/0025 Effective date: 20231012 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |